

Technology Assessment



**Technology
Assessment Program**

Long-Term Oxygen Therapy for Severe COPD

**Agency for Healthcare
Research and Quality
540 Gaither Road
Rockville, Maryland 20850**

June 11, 2004

Long-Term Oxygen Therapy for Severe COPD

FINAL REPORT

June 11, 2004

Tufts-New England Medical Center EPC

Joseph Lau, MD

Priscilla W. Chew, MPH

Chenchen Wang, MD, MS

Alexander C. White, MD

This report is based on research conducted by the Tufts-New England Medical Center Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0022). The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decision-makers; patients and clinicians, health system leaders, and policymakers, make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

Table of Contents

Background	3
Methods	6
Results	12
PAO ₂ ≤ 55 mmHg	15
PaO ₂ 56-59 mmHg	23
PaO ₂ 60-64 mmHg	26
Adverse Effects	28
Conclusions	29
References	31

Appendix I. Evidence Tables

Evidence Table 1. Randomized Controlled Trials PaO₂ ≤ 55 mmHg

Evidence Table 2. Randomized Controlled Trials PaO₂ 60-64 mmHg

Evidence Table 3. Cohort Studies PaO₂ ≤ 55 mmHg

Evidence Table 4. Cohort Studies PaO₂ 56-59 mmHg

Appendix II. List of Rejected Articles

BACKGROUND

Oxygen is an essential component of oxidative metabolism and is used as a treatment in patients with chronic lung disease. Chronic obstructive lung disease (COPD) is the most common chronic lung disease in the US and is the most common indication for supplemental oxygen. Criteria have been developed to help identify patients with COPD who may benefit from long-term oxygen therapy (LTOT). These criteria are based on the known detrimental pathophysiological effects of chronic hypoxemia. The hemoglobin molecule carries the majority of oxygen in the blood and is exquisitely designed to remain more than 90% saturated with oxygen provided the partial pressure of oxygen (PaO_2) in arterial blood is close to or above 55 to 60 mm Hg. Once the PaO_2 in arterial blood starts to fall below the 55 to 60 mm Hg threshold there is a steep reduction in the saturation of the hemoglobin molecule. Hemoglobin saturations of less than 90% are thought to result in a significant reduction in tissue oxygen delivery. By increasing the concentration of oxygen in inhaled air, supplemental oxygen improves both the PaO_2 of oxygen dissolved in arterial blood and the degree of oxygen saturation of the hemoglobin molecule (SaO_2). These effects in turn improve the oxygen delivery to organs and tissues allowing oxidative metabolism to continue in the setting

of chronic lung disease. The criteria based on these physiological observations have been developed in an attempt to identify patients who may benefit from supplemental oxygen by preventing deaths due to chronic hypoxemia and heart disease related to cor pulmonale. It is generally accepted that COPD patients with $\text{PaO}_2 \leq 55$ mmHg, or those with PaO_2 of 56 to 59 mmHg with evidence of end organ disease (e.g., pulmonary hypertension, cor pulmonale, polycythemia (hematocrit > 55%), arrhythmias, congestive heart failure, or impaired mental status) benefit from supplemental oxygen.

The cost to the health care system of providing supplemental oxygen to patients with COPD for up to 24 hours per day for many years is substantial. These costs include the cost of oxygen itself, the oxygen delivery systems to allow the patients to use the oxygen during activities of daily living or at night, and the many private vendors who service the equipment and monitor the patients.

CMS has developed a national coverage policy in 1985 based on discussions with experts and clinical evidence. CMS presently requested a technology assessment from AHRQ to summarize the available clinical and scientific evidence on the appropriateness and effective use of LTOT in patients with COPD. This summary will be presented as background for

discussion to an expert working group convened by NHLBI to discuss LTOT. In particular, CMS would like the report to address the following issues:

- Identify and analyze studies of long-term oxygen use that may have substantial impact on public health or health care costs.
- Identify and analyze studies that examine the efficacy or effectiveness of long-term oxygen on specific indications, in particular COPD.
- Identify and analyze studies to determine if long-term oxygen therapy is beneficial, and if there are any adverse effects to long-term oxygen therapy.
- Identify and analyze studies that examine the impact of long-term oxygen therapy on the progression of COPD.
- Address any additional specific assessment questions formulated by the project team in consultation with AHRQ.

METHODS

We conducted a systematic review of the literature to identify clinical studies in humans to address the above issues. The research questions could be succinctly rephrased as: What is the evidence on the outcomes and adverse effects in COPD patients treated with LTOT? In consultation with representatives from AHRQ, CMS, and NHLBI, we developed the following literature review criteria. These criteria include specifications of design, patient population/disease characteristics, types of LTOT and comparators, and outcomes of the studies to be reviewed.

Inclusion Criteria for Outcomes Studies

We accepted studies that reported the evaluation of LTOT in hypoxemic COPD patients on relevant outcomes of interest. Specific criteria for the patient population, interventions, outcomes, and study designs are discussed below.

Hypoxemic COPD Patients

We included LTOT studies of adult COPD patients based on 3 levels of hypoxemia: PaO_2 (mmHg) ≤ 55 , 56 – 59, and 60 – 64. We accepted the definition of COPD as defined by the study authors, this generally included

patients with chronic bronchitis and emphysema. FEV₁ or % of predicted FEV₁ were not used as an entry criterion in our report. Studies that used the inclusion criteria of PaO₂ ≤ 55 mmHg also typically included patients with PaO₂ between 56 and 59 if they demonstrated evidence of tissue hypoxia. We included cohort studies that evaluated mixed population (e.g., cancer, heart failure) if they reported stratified data for COPD patients or if at least 80% of the patients have COPD at hypoxemic levels of our interest.

Long-term Oxygen Therapy

LTOT is the use of oxygen outside the hospital setting in patients with COPD who are otherwise medically stable. Oxygen can be given while the patient is at rest, ambulating or sleeping at night. Oxygen may be delivered to the patient via nasal cannula, facemask, non-invasive positive pressure ventilation, or through the transtracheal route. It is generally accepted that patients who meet the criteria for LTOT should receive continuous supplemental oxygen 24 hours per day. However, the minimum number of hours of oxygen use needed to qualify for LTOT is not well defined. In addition, the number of hours of actual use of LTOT each day is dependent on patient adherence. For the purpose of this report we included all studies that were defined by the study authors as LTOT, including studies that

used nocturnal oxygen only. We included studies that provided oxygen using refillable cylinders, concentrators, or liquid oxygen systems.

Outcomes

Outcomes assessed in this report included survival and non-survival outcomes. Non-survival outcomes include: hospitalization episodes, length of stay, quality of life, exercise capacity, neuro-cognitive outcomes, depression, changes in pulmonary function (e.g., FEV₁) and other physiologic measurements (e.g., pulmonary artery pressure, hematocrit), and progression of pulmonary hypertension (cor pulmonale). In consultation with NHLBI staff, PaO₂ and PaCO₂ were not included as outcomes of interest.

Study Design

We included randomized controlled trials (RCTs) to provide direct comparisons of LTOT with standard care or alternative interventions. Prospective and retrospective cohorts (including LTOT patients registries) of patients using LTOT are used to derive additional information about survival and to compare baseline with follow-up results of various endpoints. For mortality outcomes, the percentages of mortality or survival

at defined time periods in the cohort were extracted. To qualify for evidence to be used for non-survival outcomes, cohort studies must report either results at baseline and at follow-up, or results of a defined comparison group. The LTOT arm of a RCT that do not meet the inclusion criteria (e.g., the main purpose of a study was to compare modes of oxygen delivery rather than the effects of LTOT) may nonetheless be included as a prospective cohort to provide additional information on survival and other outcomes. To be considered, each study must have at least 10 patients in each study arm (i.e., 10 in a cohort study and 20 in a parallel group randomized trial). To be considered for survival outcome, a study must have followed patients for at least 6 months.

Inclusion Criteria For Adverse Effect Studies

We accept adverse effects data in all the studies evaluated for clinical outcomes and any study that explicitly reported on adverse effects attributed to oxygen use. We excluded adverse effects related to oxygen delivery methods (e.g., complications of transtracheal method).

Excluded Studies

We excluded studies in which the main purpose was the evaluation of LTOT in patients with kyphoscoliosis or obesity-related obstructive sleep apnea, comparisons of different forms of oxygen delivery systems, or the evaluation of other interventions without outcomes specific to LTOT arms. Cross-sectional studies that do not provide longitudinal follow-up data for comparisons are excluded.

Several sets of articles were publications on the same or overlapping populations. From each set, we selected the article with the most comprehensive reporting of data and used other articles for supplemental information.

Literature search

We performed a MEDLINE search on February 27, 2004 for English language studies that evaluated the use of LTOT in patients with COPD. Search terms related to “long-term” included: ambulatory, continuous, domiciliary, home, long-term, and nocturnal. In addition, we reviewed the references of published systematic reviews, retrieved clinical trial articles, selected review articles, and clinical practice guidelines on this topic for potentially relevant studies.

Evidence Tables

Data extracted from each study that met the review criteria are summarized in evidence tables included in the appendix of this report. The evidence tables provide information for each of the studies on selected baseline patient characteristics, inclusion and exclusion criteria, study design, intervention, comparator, and outcomes. Evidence tables are grouped according to their study designs (randomized controlled trials or cohort studies) and then according to the 3 PaO₂ levels. Within each evidence table, the studies are ordered chronologically in ascending order according to their publication year.

RESULTS

The MEDLINE search yielded a total of 1,575 citations. After reviewing the abstracts, we retrieved 146 full articles for further evaluation. Thirty-nine studies that met the final inclusion criteria are summarized in this report. Six randomized controlled trials (RCTs) involving 541 patients and 24 prospective and 10 retrospective cohort studies with about 25,000 patients reported on deaths and other outcomes. Data from these studies are shown in Evidence Tables 1-4 in the appendix.

We describe in this section the results of the studies grouped by 3 levels of PaO₂ (mmHg): ≤ 55, 56 – 59, and 60 – 64. Within each of the PaO₂ levels, mortality results are presented first followed by other outcomes. Table 1 below summarizes the number of studies and outcomes available in each of the PaO₂ levels.

Table 1. Studies of LTOT for COPD Patients Included in this Report

Population PaO ₂ mmHg	RCTs # studies (# patients)		Cohort Studies # studies (# patients)	
	Mortality	Other Outcomes	Mortality	Other Outcomes
≤ 55	<p>2 (n=290) NOTT 1980 MRC 1981</p>	<p>Hospital admission 2 (n=290) NOTT 1980 MRC 1981</p> <p>HRQL 1 (n=203) NOTT 1980, 1983</p> <p>Exercise capacity 1 (n=10) Cuvelier 2002</p> <p>Pulmonary function 3 (n=320) Fleetham 1980 NOTT 1980 MRC 1981</p>	<p>17 prospective cohorts (n=6,723) Krop 1973 Ashutosh 1983 Weitzenblum 1985 Vergeret 1989 Gorecka 1992 Dubois 1994 Dallari 1994 Simonds 1995 Oswald- Mammosser 1995 Borak 1996 Clini 1996 Okubadejo 1996 Heaney 1997 Aida 1998 Strom 1998 Zielinski 1998 Farrero 2001</p> <p>8 retrospective cohorts (n=18,300) McKeon 1987 Corrado 1994 Buyse 1995 Miyamoto 1995 Chailleux 1996 Hjalmarsen 1999a Crockett 2001 Demirel 2003</p>	<p>Hospital admission 4 (n=319) Stewart 1975 Weitzenblum 1985 Clini 1996 Ringbaek 2002</p> <p>HRQL 6 (n=223) Krop 1973 Lahdensuo 1989 Borak 1996 Okubadejo 1996 Hjalmarsen 1999b Farrero 2001</p> <p>Sleep 1 (n=12) Lin 1996</p> <p>Pulmonary function 8 (n=200) Krop 1973 Weitzenblum 1991 Simonds 1995 Clini 1996 Okubadejo 1996 Farrero 2001 Sergi 2002 Bratel 2003</p>
56 – 59	ND	ND	<p>prospective cohorts 1 (n=46) Sliwinski 1992</p>	<p>Pulmonary function 1 (n=14) Sandek 2001</p> <p>Hospital admission 1 (n=46) Sliwinski 1992</p>

	RCTs # studies (# patients)		Cohort Studies # studies (# patients)	
Population PaO ₂ mmHg	Mortality	Other Outcomes	Mortality	Other Outcomes
60 – 64	2 (n=211) Gorecka 1997 Chaouat 1999	Pulmonary function 1 (n=76) Chaouat 1999	retrospective cohorts 1 (n=48) Hjalmarsen 1999a	ND

ND – no data

HRQL – health related quality of life

Patients with PaO₂ ≤55 mmHg

Two RCTs enrolled 290 COPD patients with PaO₂ ≤ 55 treated with LTOT reported data on mortality outcomes (NOTT 1980, MRC 1981).

Seventeen prospective cohort studies with a total of 6,723 COPD patients with PaO₂ ≤ 55 treated with LTOT reported mortality data (Table 2).

Mortality Outcomes - RCTs

The Nocturnal Oxygen Therapy Trial (NOTT) selected 203 patients from 1,043 patients with hypoxemic COPD evaluated in 6 centers (NOTT 1980). One hundred and two patients were randomized to receive nocturnal oxygen therapy (NOT) and 101 patients to continuous oxygen therapy (COT). Patients were randomized in blocks of 4 within each study center. Neither the investigators nor the patients were blinded. Oxygen was delivered via nasal prongs using oxygen concentrators, liquid oxygen systems, or compressed gas. Patients were evaluated at baseline and every 6 months thereafter.

Seventy-nine percent of the patients were male and the average age was 65 years. The baseline general and cardiopulmonary characteristics were well balanced between the study groups with mean PaO₂ of 51.5 mmHg in the NOT group and 50.8 mmHg in the COT group, mean PaCO₂

of 43 mmHg and % predicted FEV₁ of 30 in both groups. The overall baseline rating of the neuropsychiatric characteristics was higher in the NOT group compared with the COT group (4.5 vs. 4.2) and was marginally significant (P=0.06).

Surviving patients were followed for a minimum of 12 months with a mean of 19 months. Adherence to oxygen therapy was noted to be “very good”. Patients in the COT group received an average of 18 hours and patients in the NOT group received 12 hours of oxygen therapy daily. Overall, 21 patients died in the COT group and 41 patients died in the NOT group. The 12-month mortality was 12% in the COT group and 21% in the NOT group (odds ratio 0.53, 95% CI 0.25-1.11). At 24 months, the mortality was 22% in the COT group and 41% in the NOT group (odds ratio 0.45, 95% CI 0.25-0.81).

The Medical Research Council trial from UK randomized 87 patients in 3 centers to receive LTOT or no placebo/supplemental-oxygen controls (MRC 1981). Oxygen was administered via nasal prongs using oxygen concentrators, liquid oxygen systems or oxygen cylinders for at least 15 hours/day in the treatment group. Neither the investigators nor the patients were blinded.

Forty-two patients were randomized to LTOT and 45 patients served as no-treatment controls. The average age was 58 and 76% of the patients were men. The mean baseline PaO₂ measurements of the 2 groups were similar (50.2 mmHg in the LTOT group vs. 51.6 mmHg in the control group). The mean baseline FEV₁ in men who received LTOT was slightly higher than the control (0.76 L vs. 0.65 L). Although the mean baseline PaCO₂ was similar between groups (55 mmHg), this was higher than that of the NOTT study population (43 mmHg).

During a 5-year follow up, 19 of the 42 patients (45%) on LTOT died, compared with 30 of the 45 controls (67%) (odds ratio 0.42, 95% CI 0.18-0.98). The benefit for men was not seen until after 500 days whereas the benefit for women was demonstrated almost immediately. One patient was withdrawn from the LTOT group due to failure to comply.

The patients in both trials were mostly similar and they achieved similar degree of mortality reduction. However, the control group in the NOTT trial used NOT whereas the control group in MRC trial had no supplemental oxygen. While one can conclude that at least 15 hours of COT is beneficial, one cannot directly infer that there is a continuous dose effect (i.e., whether 18 hours of COT is better than 15 hours or whether 12 hours of NOT is better than no supplemental oxygen).

Table 2. Cohort studies that reported mortality data of LTOT for COPD patients with PaO₂ ≤ 55 mmHg

Study Year Country	Study Size	Study duration (years)	Mortality %			
			1 y	2 y	3 y	5 y
Prospective Cohort Studies						
Aida 1998 Japan	4,552	6	12	38		61
Strom 1991, 1993, 1998 Sweden	405	2.3	23	44		62
Gorecka 1992 Poland	315	1	21			
Dubois 1990 1994 Belgium	270	3	30	50	57	83
Heaney 1997 N Ireland	178	> 8	31 (10 mo)	50 (20 mo)		67
Dallari 1994 Italy	166	2		22	33	
Borak 1996 Poland	1224	1	27			
Zielinski J 1998 Poland	95	6		23		
Oswaldmammosser 1995 France	84	5			29	52
Vergeret 1989 Denmark	75	2	12			
Farrero 2001 Spain	62	1	34			
Simonds 1995 England	33	5	15	24	32	55
Okubadejo 1996 UK	23	0.5	17 (6 mo)			

Long-term oxygen therapy for COPD

Study Year Country	Study Size	Study duration (years)	Mortality %			
			1 y	2 y	3 y	5 y
Clini 1996 Italy	34	1.5	17-23			
Ashutosh 1983 USA	28	2		Responders 13 (n=17) Non-responders 78 (n=11)		
Weitzenblum 1985 1991 France	24	1			25 (33 mo, n=16)	65 (73 mo)
Krop 1973 Stewart 1975 US	12	2	8.3	33		
Retrospective Cohort						
Chailleux 1996 2003 France	12,403	10	~25	~41	~70	
Miyamoto 1995	5,055	7	~13	~25	~36	~58
Crockett 2001 Australia	505	10	25	49		81
Demirel 2003 Turkey	127	1.4	5.5			
McKeon 1987 Australia	84	14	6	20		64
Corrado 1994 Italy	35	4	~6	~17	~37	~49 (4 y)
Hjalmarsen 1999a Sweden	76	8		27		50
Buyse 1995 Belgium	15	3	13	40		

Mortality Outcomes - Cohort Studies

Seventeen prospective cohort studies were conducted in Australia, Europe, Japan, and the US (Table 2). These studies included a total of 6,723 patients with study size ranging from 12 to 4,552. The studies followed patients from 6 months to 12 years. LTOT therapy was generally given 14 to 24 hours daily. One study reported greater than 8 hours of oxygen at night and 1 study did not report oxygen usage data. The reported mortality varies between 6 to 34% at 1 year of follow-up in 12 studies, 20 to 50% at 2 years in 9 studies, 25 to 57% at 3 years in 5 studies, and 52 to 83% at 5 years in 7 studies. The largest prospective cohort study of 4,552 patients came from Japan with a mean follow up of 2.4 years (Aida 1998). They reported 1-, 2-, and 5-year mortality of 12, 38, and 61%, respectively.

Eight retrospective cohort studies with 6 months to 10 years of follow-up reported mortality outcomes in 18,300 patients (Table 2). Four studies reported patients were prescribed at least 15 hours of oxygen daily while the other 4 studies did not report this information. The range of mortality rates of the retrospective cohort studies at different follow-up time points are similar to those of the prospective cohort studies. The largest retrospective cohort study with 12,403 patients from France reported 1-, 2-, and 3-year mortality rates of 25, 41, and 70%, respectively (Chailleux

1996). The second largest retrospective cohort study of 5,055 patients was conducted in Japan (Miyamoto 1995). This study reported 1-, 2-, 3- and 5-year mortality rates of 13, 25, 36, and 58%, respectively. This study shared the same patient registry as the report by Aida et al. (1998) and probably had a large degree of overlap in the patients studied.

Other (non-mortality) Outcomes

Hospital Admission - RCTs

Two RCTs reported results on hospitalization. The NOTT and MRC trials both reported that LTOT decreases the number of days of hospitalization among hypoxemic COPD patients although neither trial reported results numerically. The NOTT study reported that patients on COT tended to be hospitalized less often and to have fewer long hospitalizations than NOT patients, although differences were not statistically significant (NOTT 1980). The MRC trial reported that the duration of hospitalization due to exacerbations of respiratory failure was not affected by oxygen therapy (MRC 1983).

Hospital Admission – Cohort Studies

Three prospective (Krop 1973, Weitzenblum 1985, Clini 1996) and 1 retrospective (Ringbaek 2002) cohort studies reported hospitalization data. All of these studies reported that LTOT reduced the frequency of hospitalization and the number of hospital days. Krop et al. (1973) reported that the average number of days hospitalized per patient decreased from about 30 days before LTOT to 20 days 1 year after LTOT oxygen was instituted in a cohort of 12 patients. In a cohort of 16 patients, Weitzenblum et al. (1985) reported that the average number of hospitalization days per year decreased from 18 to 9 after LTOT. Clini et al. (1996) compared two 18-month periods before and after LTOT in a cohort of 17 patients. They reported that the average number of hospital admissions decreased from 2 to 1 and the average number of days in hospital decreased from 55 to 18 after LTOT. In a retrospective cohort study of 246 patients that focused on the effect of LTOT on hospitalization, Ringbaek et al. (2002) reported that the average number of hospital admissions per patient per year decreased from 2.1 to 1.6 and the average number of days hospitalized decreased from 23.7 to 13.4 after LTOT. Similar magnitude of decreases were seen in patients who received 15-24 hours of oxygen daily compared with those who received less than 15 hours.

Health Related Quality of Life (HRQL) and Neuropsychological - RCT

The NOTT study was the only RCT that reported HRQL data. It assessed Minnesota Multiphasic Personality Inventory (MMPI) scale, Sickness Impact Profile (SIP) and Profile of Mood States (NOTT 1980). The study reported neuropsychological deficits in hypoxemic COPD patients and observed small (“average about 10%”) improvements in neuropsychological function and quality of life scores when data from patients receiving COT or NOT were combined. The authors hypothesized that these small changes might have been due to the more intensive medical and nursing care that the patients received as study participants rather than the direct effect of oxygen. Numerical data for HRQL measures were reported for the baseline but not for the end of the trial.

Health Related Quality of Life (HRQL) and Neuropsychological – Cohort Studies

Six prospective cohort studies reported HRQL or neuropsychological outcomes on 223 patients (Krop 1973, Lahdensuo 1989, Borak 1996, Okubadejo 1996, Hjalmsen 1999b, Farrero 2001). LTOT was provided for various durations from 3 months to 2 years in these studies. These studies reported HRQL and psychological and psychosocial response data,

including: MMPI, Wechsler Adult Intelligence Scale, Wechsler Memory Scale, Bourdon-Wiersma Test, Beck Depression Inventory, Chronic Respiratory Questionnaire, St. George's Respiratory Questionnaire, SIP and the Hospital Anxiety and Depression Scale (HADS).

The study by Borak et al. (1996) from Poland reporting data on 90 patients represents the largest cohort of COPD patients with $\text{PaO}_2 \leq 55$ mmHg that have been evaluated for neuropsychological status before and after the initiation of LTOT. Of the 124 initially eligible patients, cognitive function, psychological status, and attitudes were assessed before and after one year in 90 survivors using a battery of instruments. The authors found major cognitive dysfunction and severe emotional disturbances at baseline. Patients were found to have a low level of concentration, narrow interests, reduced planning ability, disturbed direct memory, and reduced visual/spatial coordination. After one year of oxygen therapy, improvements in cognitive function were limited to recent memory and speed of work. A significant improvement in self-esteem and emotional status were observed following treatment. It was noted that improvements in psychological status was observed despite some deterioration in pulmonary function. The authors also concluded that it is difficult to separate the effect of oxygen from the overall benefits of specialist medical care.

Two other small studies of 12 patients (Krop 1973) and 10 patients (Hjalmarsen 1999b) also reported that LTOT is associated with an improvement in intellectual functioning, depression and HRQL. The changes observed in these studies did not reach statistical significance due to the small study size. However, 3 other studies with a total of 111 patients) reported that there was no significant change in the HRQL and psychological and psychosocial variables in patients treated with LTOT (Lahdensuo 1989, Okubadejo 1996, Farrero 2001).

Sleep Outcomes

We identified only 1 prospective cohort study that investigated the effect of LTOT on sleep (Lin 1996). The study was conducted in Taiwan on 12 patients with severe COPD. Total sleep time, sleep efficiency, and sleep latency were compared before therapy and after 2 weeks of oxygen therapy. The study found that sleep efficiency and sleep architecture did not change with oxygen therapy.

Exercise Capacity

One randomized crossover study of 10 COPD patients on LTOT reported physical exercise capacity outcome (Cuvelier 2002). The patients

performed 3 successive 6-min walking tests separated by 60 minutes of rest. The first test was conducted in room air and the other tests in a random order with 2 types of refillable oxygen cylinders. Mean walking distance was significantly increased when performed with either cylinders (375 ± 97 meters [$p=0.02$] or 374 ± 81 meters [$p=0.03$]) compared with room air (335 ± 90 meters).

Pulmonary Function and Physiologic Measurements – RCTs

Three RCTs (Fleetham 1980, NOTT 1980, MRC 1981) reported on pulmonary function and physiologic measurements. Fleetham randomized 30 COPD patients to treatment with either 12 hours of NOT or 24 hours of COT (Fleetham 1980). There were no significant changes in pulmonary function ($FEV_1\%$) in either group over the 6 months period. Among patients who received LTOT in the MRC trial, the red cell mass fell slightly and the mean PAP remains unchanged, whereas in the control group the red cell mass and the PAP rose. These changes were not significantly different between groups. The NOTT study reported that in patients who received COT, comparing with patients who received NOT, the pulmonary vascular resistance was significantly decreased at 6 months (-11% vs. $+6.5\%$;

p=0.04). Hematocrit was also significantly decreased in the COT group when compared with the NOT group (9.2 % vs. 2%, p=0.008).

Pulmonary Function and Physiologic Measurements – Cohort Studies

Eight prospective cohort studies (Krop 1973, Weitzenblum 1985, Simonds 1995, Clini 1996, Okubadejo 1996, Farrero 2001, Sergi 2002, Bratel 2003) reported pulmonary function data on 218 patients. No significant changes were reported in FEV₁% in 5 studies (Krop 1973, Weitzenblum 1985, Simonds 1995, Clini 1996, Okubadejo 1996) while 2 other studies (Farrero 2001, Sergi 2002) found significant improvements in FEV₁%. Bratel reported a non-significant decrease in hemoglobin (15.1 g to 14.6 g) and no change in FEV₁% in 12 patients.

Patients with PaO₂ between 56 and 59 mmHg

Mortality Outcomes

There was no RCT in this category of PaO₂. One prospective cohort study of 46 COPD patients with mean PaO₂ of 57 mmHg investigated whether the acute effect of oxygen on pulmonary arterial pressure (PAP) is related to survival (Sliwinski 1992). Patients who experienced a decrease of 5 mmHg or more of PAP while breathing supplemental oxygen were classified as responders. After 2 years of LTOT, 12 patients died in the non-responders group (39 patients) and 3 died in the responders group (7 patients). The 2-year survival rate was 69% in non-responders and 57% in responders.

Hospital Admission

The study by Sliwinski (1992) also assessed the relationship of responders to LTOT (based on PAP changes) with hospitalization. After 2 years of LTOT, the subjects from the non-responders group were admitted to the hospital 55 times versus 6 times in the responders group during the study period of 2 years. On average there were 1.4 versus 0.8 admissions per patient in the non-responders versus responders group.

Pulmonary Function and Physiologic Measurements

We found 1 prospective cohort studies in this category of PaCO₂ reporting the effect of LTOT on pulmonary function and physiological measurements. In a study of 14 COPD patients receiving 6 months of LTOT (Sandek 2001), no significant changes in dynamic or static lung volumes, hypercapnic ventilatory response or hypercapnic drive response were detected. The author concluded that 6 months of low flow oxygen therapy in stable COPD patients is not accompanied by any clinically important changes in pulmonary physiology.

Patients with PaO₂ between 60 and 64 mmHg

Mortality Outcomes - RCT

Two RCTs reported mortality outcomes in this category of PaO₂. One RCT evaluated 76 COPD patients in 6 hospitals in 4 European countries (Chaouat 1999). Forty-one patients were randomized to oxygen concentrator for 8-10 hours per night and 35 patients to no oxygen control group. There was no significant difference in mortality between the treated and control groups on an intention to treat analysis (odds ratio 1.1, 95% CI 0.37-3.4). The second trial randomized 135 patients into LTOT (at least 17 hours of oxygen daily) or usual care (Gorecka 1997). The patients were followed for 3 years or until death. No significant difference in mortality was found between the 2 groups (odds ratio 1.1, 95% CI 0.37-3.4).

Mortality Outcomes - Retrospective cohort

Hjalmarsen et al. (1999a) analyzed a retrospective cohort of 124 patients using LTOT for 6 years by dividing it into 2 groups with PaO₂ ≤ 55 mmHg and PaO₂ ≥ 56 mmHg (mean PaO₂ = 62 mmHg). Both groups had similar FEV₁ and FVC levels. The 2- and 3-year survival rates were 73% and 50%, respectively, in the PaO₂ ≤ 55 group, and 78% and 40% in the PaO₂ ≥ 56 group. The author concluded that survival during LTOT was

similar in patients with and without severe hypoxemia at the same level of loss of lung function.

Pulmonary Function and Physiologic Measurements

The RCT by Chaouat (1999) also collected pulmonary function and physiologic measurements. It reported no significant changes in FEV₁, resting and exercising PAP between LTOT and control groups.

Adverse Effects of LTOT

Two studies reported adverse effects and safety concerns with the use of LTOT. One study reported: “A negative psychological impact on the patients caused by the oxygen treatment was reported in a small proportion of the follow-up recordings (0-9%)” (Strom 1991). However, this issue was not expanded upon in the article.

One retrospective review of burn patients reported a subgroup of 23 LTOT patients with burn injuries directly related to use or handling of oxygen (Chang 2001). In this study, COPD was the most prevalent reason for home oxygen use (20 of the 23 patients). The mean age was 70 years with a range of 50 to 84 years. Causes of fire included cigarette smoking (16/23), cooking (6/23), and refilling a home oxygen unit with liquid oxygen (1/23). Twenty-one of 23 sustained partial-thickness injuries involving an average of 4% of the body surface area. Inhalation injury occurred in 13 patients with 5 of them requiring tracheal intubation and mechanical ventilation because of a combination of direct inhalation injury, acute worsening of their underlying pulmonary disease, and subsequent lung infection. Two of the 23 patients died during their hospitalizations. Both were injured while smoking during the use of their home oxygen.

CONCLUSIONS

Evidence from RCTs to guide the use of LTOT in patients with COPD is very limited. Most of the studies included in this report focused on the severely hypoxemic populations with $\text{PaO}_2 \leq 55$ mmHg. Only 2 RCTs published over 20 years ago evaluated patients with PaO_2 between 56 and 59 mmHg. Both of these trials reported similar reduction of overall mortality. Two RCTs conducted in patients with PaO_2 between 60 and 64 mmHg reported no mortality benefits.

Twenty-five prospective or retrospective cohort studies with almost 25,000 patients reported survival data for COPD patients with $\text{PaO}_2 \leq 55$. It can be readily appreciated from these cohort studies that the overall survival in the severely hypoxemic population on LTOT is poor, compared with the normal population. The survival rates at any common time point varied widely across the studies suggesting that large variations exist in the inclusion criteria, populations studied, forms of intervention, and assessment of outcomes. This degree of heterogeneity and the lack of a comparison group make it difficult to generalize the results of individual studies.

Limited evidence from RCTs and cohort studies on non-mortality outcomes in patients with $\text{PaO}_2 \leq 55$ mmHg suggest that LTOT may reduce

the number of hospital admission or the length of hospitalization, improve certain aspects of neuropsychological function.

Serious adverse effect appears to be limited to the well-known problem that oxygen is highly flammable and should not be used around open flames. Occasional thermal burn injuries may also occur with handling of liquid oxygen systems.

It is unnecessary to conduct additional placebo controlled RCTs in patients with $\text{PaO}_2 \leq 55$ mmHg. However, there is currently no randomized evidence of survival benefit in patients with PaO_2 56-59 mmHg. The methodological quality of the studies could be substantially improved. Better standardization of inclusion criteria and outcome measures will facilitate the interpretation of results across studies. Several studies have analyzed clinical and physiologic measures as predictors of responses to survival and non-survival benefits in LTOT users. A priori stratification by potential predictors of outcomes might be useful to gain insights to optimize management.

REFERENCES

- Aida A, Miyamoto K, Nishimura M, Aiba M, Kira S, Kawakami Y. Prognostic value of hypercapnia in patients with chronic respiratory failure during long-term oxygen therapy. *Am J Respir Crit Care Med* 1998;158:188-93.
- Ashutosh K, Mead G, Dunsky M. Early effects of oxygen administration and prognosis in chronic obstructive pulmonary disease and cor pulmonale. *Am Rev Respir Dis* 1983;127:399-404.
- Borak J, Sliwinski P, Tobiasz M, Gorecka D, Zielinski J. Psychological status of COPD patients before and after one year of long-term oxygen therapy. *Monaldi Arch Chest Dis* 1996;51:7-11.
- Bratel T, Ljungman S, Runold M, Stenvinkel P. Renal function in hypoxaemic chronic obstructive pulmonary disease: effects of long-term oxygen treatment. *Respir Med* 2003;97:308-16.
- Buyse B, Demedts M. Long-term oxygen therapy with concentrators and liquid oxygen. *Acta Clinica Belgica* 1995;50:149-57.
- Chailleux E, Fauroux B, Binet F, Dautzenberg B, Polu JM. Predictors of survival in patients receiving domiciliary oxygen therapy or mechanical ventilation. A 10-year analysis of ANTADIR Observatory. *Chest* 1996; 109:741-9.
- Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. *Chest* 2003;123:1460-6.
- Chang TT, Lipinski CA, Sherman HF. A hazard of home oxygen therapy. *J Burn Care Rehab* 2001;22:71-4.
- Chaouat A, Weitzenblum E, Kessler R, Charpentier C, Enrhart M, Schott R et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. *Eur Respir J* 1999;14:1002-8.
- Clini E, Vitacca M, Foglio K, Simoni P, Ambrosino N. Long-term home care programmes may reduce hospital admissions in COPD with chronic hypercapnia. *Eur Respir J* 1996;9:1605-10.

- Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. *Ann Intern Med* 1980;93:391-8.
- Corrado A, De Paola E, Messori A, Bruscoli G, Nutini S. The effect of intermittent negative pressure ventilation and long-term oxygen therapy for patients with COPD. A 4-year study. *Chest* 1994;105:95-9.
- Crockett AJ, Cranston JM, Moss JR, Alpers JH. Survival on long-term oxygen therapy in chronic airflow limitation: from evidence to outcomes in the routine clinical setting. *Internal Medicine Journal* 2001;31:448-54.
- Crockett AJ, Cranston JM, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2003. Oxford: Update Software.
- Cuvelier A, Nuir JF, Chakroun N, Aboab J, Onea G, Benhamou D. Refillable oxygen cylinders may be an alternative for ambulatory oxygen therapy in COPD. *Chest* 2002;122:451-6.
- Dallari R, Barozzi G, Pinelli G, Merighi V, Grandi P, Manzotti M et al. Predictors of survival in subjects with chronic obstructive pulmonary disease treated with long-term oxygen therapy. *Respiration* 1994;61:8-13.
- Demirel H, Demir T, Umut S. Retrospective evaluation of patient compliance in continuous oxygen therapy. *Respiration* 2003;70:149-53.
- Dubois P, Jamart J, Machiels J, Smeets F, Lulling J. Prognosis of severely hypoxemic patients receiving long-term oxygen therapy. *Chest* 1994; 105:469-74.
- Dubois P, Machiels J, Smeets F, Delwiche JP, Lulling J. CO transfer capacity as a determining factor of survival for severe hypoxaemic COPD patients under long-term oxygen therapy. *Eur Respir J* 1990; 3:1042-7.
- Farrero E, Escarrabill J, Prats E, Maderal M, Manresa F. Impact of a hospital-based home-care program on the management of COPD patients receiving long-term oxygen therapy. *Chest* 2001;119:364-9.

- Fleetham JA, Bradley CA, Kryger MH, Anthonisen NR. The effect of low flow oxygen therapy on the chemical control of ventilation in patients with hypoxemic COPD. *Am Rev Respir Dis* 1980; 122:833-40.
- Gorecka D, Gorzelak K, Sliwinski P, Tobiasz M, Zielinski J. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. *Thorax* 1997;52:674-9.
- Gorecka D, Sliwinski P, Zielinski J. Adherence to entry criteria and one year experience of long-term oxygen therapy in Poland. *Eur Respir J* 1992; 5:848-852.
- Heaney LG, Buick JB, Lowry RC, MacMahon J. Prescription of oxygen concentrators and survival in Northern Ireland. *Ulster Med J* 1997; 66:86-91.
- Heaton RK, Grant I, McSweeney AJ, Adams KM, Petty TL. Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease. *Arch Intern Med* 1983;143:1941-7.
- Hjalmarsen A, Melbye H, Wilsgaard T, Holmboe JH, Opdahl R, Viitanen M. Prognosis for chronic obstructive pulmonary disease patients who receive long-term oxygen therapy. *Int J Tubercul Lung Dis* 1999a; 3:1120-6.
- Hjalmarsen A, Waterloo K, Dahl A, Jorde R, Viitanen M. Effect of long-term oxygen therapy on cognitive and neurological dysfunction in chronic obstructive pulmonary disease. *Eur Neurol* 1999b;42:27-35.
- Krop HD, Block AJ, Cohen E. Neuropsychologic effects of continuous oxygen therapy in chronic obstructive pulmonary disease. *Chest* 1973; 64:317-22.
- Lahdensuo A, Ojanen M, Ahonen A, Laitinen J, Poppius H, Salorinne Y et al. Psychosocial effects of continuous oxygen therapy in hypoxaemic chronic obstructive pulmonary disease patients. *Eur Respir J* 1989; 2:977-80.
- Lin CC. Comparison between nocturnal nasal positive pressure ventilation combined with oxygen therapy and oxygen monotherapy in patients with severe COPD. *Am J Respir Crit Care Med* 1996;154(2:Pt 1):353-8.

- Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. *Lancet* 1981;1(8222):681-6.
- McKeon JL, Saunders NA, MurreeAllen K. Domiciliary oxygen: rationalization of supply in the Hunter region from 1982-1986. *Medical J Australia* 1987;146:73-8.
- Miyamoto K, Aida A, Nishimura M, Aiba M, Kira S, Kawakami Y. Gender effect on prognosis of patients receiving long-term home oxygen therapy. The Respiratory Failure Research Group in Japan. *Am J Respir Crit Care Med* 1995;152:972-6.
- Okubadejo AA, Paul EA, Jones PW, Wedzicha JA. Does long-term oxygen therapy affect quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia? *Eur Respir J* 1996; 9:2335-9.
- OswaldMammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. *Chest* 1995;107:1193-8.
- Petty TL, Bliss PL. Ambulatory oxygen therapy, exercise, and survival with advanced chronic obstructive pulmonary disease (the Nocturnal Oxygen Therapy Trial revisited). *Respir Care* 2000;45:204-11.
- Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease? *Eur Respir J* 2002;20:38-42.
- Sandek K, Bratel T, Hellstrom G, Lagerstrand L. Ventilation-perfusion inequality and carbon dioxide sensitivity in hypoxaemic chronic obstructive pulmonary disease (COPD) and effects of 6 months of long-term oxygen treatment (LTOT). *Clin Physiol* 2001;21:584-93.
- Sergi M, Rizzi M, Andreoli A, Pecis M, Bruschi C, Fanfulla F. Are COPD patients with nocturnal REM sleep-related desaturations more prone to developing chronic respiratory failure requiring long-term oxygen therapy? *Respiration* 2002;69:117-22.

Simonds AK, Elliott MW. Outcome of domiciliary nasal intermittent positive pressure ventilation in restrictive and obstructive disorders. *Thorax* 1995;50:604-9.

Sliwinski P, Hawrylkiewicz I, Gorecka D, Zielinski J. Acute effect of oxygen on pulmonary arterial pressure does not predict survival on long-term oxygen therapy in patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1992;146:665-9.

Sliwinski P, Hawrylkiewicz I, Gorecka D, Zielinski J. The acute effect of oxygen on pulmonary arterial pressure does not predict survival on long-term oxygen therapy in COPD patients. *Monaldi Arch Chest Dis* 1993;48:451-2.

Stewart BN, Hood CI, Block AJ. Long-term results of continuous oxygen therapy at sea level. *Chest* 1975;68:486-92.

Strom K, Boe J. Quality assessment and predictors of survival in long-term domiciliary oxygen therapy. The Swedish Society of Chest Medicine. *Eur Respir J* 1991;4:50-8.

Strom K. Oral corticosteroid treatment during long-term oxygen therapy in chronic obstructive pulmonary disease: a risk factor for hospitalization and mortality in women. *Respir Med* 1998;92:50-6.

Strom K. Survival of patients with chronic obstructive pulmonary disease receiving long-term domiciliary oxygen therapy. *Am Rev Respir Dis* 1993;147:585-91.

Tarpy SP, Celli BR. Long-term oxygen therapy. *N Engl J Med* 1995; 333:710-4.

Vergeret J, Brambilla C, Mounier L. Portable oxygen therapy: use and benefit in hypoxaemic COPD patients on long-term oxygen therapy. *Eur Respir J* 1989; 2:20-5.

Weitzenblum E, Oswald M, Apprill M, Ratomaharo J, Kessler R. Evolution of physiological variables in patients with chronic obstructive pulmonary disease before and during long-term oxygen therapy. *Respiration* 1991; 58(3-4):126-131.

Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1985;131:493-8.

Zielinski J, Tobiasz M, Hawrylkiewicz I, Sliwinski P, Palasiewicz G. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients: a 6-year prospective study. *Chest* 1998;113:65-70.

Long-term Oxygen Therapy for COPD

Evidence Tables

Evidence Table 1. PaO₂ ≤ 55 mmHg Randomized Controlled Trials

PaO₂ 56-59 mmHg – No Randomized Controlled Trials

Evidence Table 2. PaO₂ 60-64 mmHg Randomized Controlled Trials

Evidence Table 3. PaO₂ ≤ 55 mmHg Cohort Studies

Evidence Table 4. PaO₂ 56-59 mmHg Cohort Studies

PaO₂ 60-64 mmHg – No Cohort Studies

Evidence Table 1. Randomized controlled trials of LTOT for COPD patients with PaO₂ ≤55 mmHg

Study Year Country	Study design		Population	Baseline		O ₂ therapy hrs/day	Outcomes		Comments
	Duration; RCT features	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Fleetham 1980 Canada	1 y F/U	Inclusion: FEV ₁ /VC < 70%, and if TLC ≥80% P nl, PaO ₂ <56 or <59 mmHg w/ankle edema > 3 wk of infection-free clinical stability on intensive bronchodilator	N=16 Male: ND Age: ND ----- N=14 Male: ND Age: ND	PaO ₂ 52±0.7 PaCO ₂ 46±1.2 ----- PaO ₂ 52±1.3 PaCO ₂ 44±1.5 SE	25±2.9 SE ----- 22±2.3 SE	COT 24 ----- NOT 12	ND ----- Mortality	<i>Pulmonary function at 6m</i> FEV ₁ % 25±2.9 (SE) NS n=11 ----- FEV ₁ % 21±3.3 (SE) NS n=12	Oxygen compliance monitored by nurses, no patients lost to F/U
NOTT 1980 Heaton 1983 US	19.3 mo average F/U; Block randomization within each 6 sites	Inclusion: >35 y, clinical diagnosis of COPD, PaO ₂ ≤ 55 mmHg or PaCO ₂ ≤ 59 plus edema, hematocrit ≥ 55%, P pulmonale on ECG, FEV ₁ /FVC <70%, TLC ≥ 80% predicted Exclusion: previous O ₂ 12h/d for 30 d prior 2 m, other disease that might influence outcomes	Total N=203 COT n=101 NOT n=102 Male: 79% Age: 65	COT PaO ₂ 51 PaCO ₂ 43 ----- NOT PaO ₂ 52 PaCO ₂ 44	COT 30 ----- NOT 30	COT 18±4.8 ----- NOT 12±2.5	<i>12 mo</i> COT 12%±3.2 (SE) NOT 21%±4.0 (SE) odds ratio 0.53 (0.25-1.11) <i>24 mo</i> COT 22%± 4.6 (SE) NOT 41%±5.5 (SE) odds ratio 0.45 (0.25-0.81)	<i>Hematocrit decrease at 18 mo</i> NOT (n=36) 2.0% COT (n=40) 9.2% p=0.008 <i>Pulmonary vascular resistance at 6 mo</i> NOT (n=49) +6.5% COT (n=52) -11% p=0.04 <i>Neuropsychological evaluation at 6 mo (n=150)</i> Small improvements noted in most measures but formal statistical test were not presented for two treatment groups. <i>HQOL</i> NS for either groups on QOL measures <i>Hospitalization</i> COT decrease trend for number of admissions and LOS compared to NOT but NS.	2 COT patients lost to F/U

Study Year Country	Study design		Population	Baseline		O ₂ therapy hrs/day	Outcomes		Comments
	Duration; RCT features	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
MRC Stuart-Harris 1981 UK	5 y F/U; table of random numbers, unblinded	Inclusion: <70, chronic bronchitis or emphysema with FEV ₁ <1.2L, PaO ₂ 40- 60 mmHg Exclusion: fibrotic or infiltrative lung disorder, pneumonconiosis, severe kyphoscoliosis, pulmonary embolism, elevated BP, coronary arterial or other life- threatening disease	N=87 Treatment: 42 Control: 45 Male: 76% Age: 58 (42-69)	PaO ₂ 51 PaCO ₂ 54	FEV ₁ L ~0.6 W ~0.7 M	>15	5 years Treatment: 45% Control: 67% OR 0.42 (0.18, 0.98)	"There are no significant different between the groups in physiological variables, hospital stay and work record."	3 centers 1 withdrawal from treatment group
Cuvelier 2002 France	ND; Cross-over, double dummy, single-blind	Inclusion: stable COPD, LTOT at home, able to perform walking tests	N=10 Male: 90% Age: 65	PaO ₂ 55± 6.3 PaCO ₂ 46± 7.4	98± 27	ND	ND	Mean walking distance test Room air 334.5±90m (A) O ₂ 374±81 m p=0.03 (B) O ₂ 375±97 m p=0.02	---

Mean and standard deviation unless otherwise noted.

Abbreviations: COT, continuous oxygen therapy; d, day(s); F/U, follow-up; LOS, length of stay; m, month(s); ND, no data; NOT, nocturnal oxygen therapy; OR, odds ratio; PAP, pulmonary artery pressure; SE, standard error; y, year.

Evidence Table 2. Randomized controlled trials of LTOT for COPD patients with PaO₂ 60-64 mmHg

Study Year Country	Study design		Population	Baseline		O ₂ therapy hours/day	Outcomes		Comments
	Duration / RCT features	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ % Predicted		Mortality	Other outcomes	
Gorecka 1997 Poland	7 y F/U, mean 41 mo; Computer central generated random numbers, not blinded	Inclusion: single diagnosis COPD, 40-80 y with airway limitation (FEV ₁ /VC post bronchodilator of <70%, PaO ₂ 56- 65 from 1987-92, F/U through 1994 Exclusion: serious disease of organs other than lungs that might influence survival	N=135 Male: 76% Age: 61	PaO ₂ 60±2.8 PaCO ₂ 44±6.7	30±9.8	14	LTOT 56% Control 49% Odds Ratio (all-cause) 1.4 (0.70-2.7)		9 regional LTOT centers, no patients lost to F/U
Chaouat 1999 Europe	35 mo F/U Table of random sampling numbers, NOT to even numbers, control to odd numbers, unblinded	Inclusion: FEV ₁ /VC ratio <60% predicted value, 2 PaO ₂ measures 56-69 (4 weeks apart), PaCO ₂ ≥45, nocturnal desaturation ≥ 30% & SaO ₂ < 90% Exclusion: left or congenital heart, or interstitial lung diseases, bronchiectasis, disease that might affect outcomes, sleep apnea	N=76 Male: ND Age: 63 NOT: 41 No NOT control: 35	PaO ₂ 63±3.3 PaCO ₂ 45±5.6	39±16	NOT 8.9±1.9	NOT 22% Control 20% Odds Ratio 1.1 (0.37-3.4)	There was no significant change in pulmonary volumes, FEV ₁ and resting and exercising PAP	12 NOT & 10 controls received LTOT due to fall in PaO ₂ levels, mortality analyses on intention to treat, similar results if LTOT exposure removed, 6 outpatient centers, 11 withdrawals, 2 lost to F/U

Evidence Table 3. Cohort studies of LTOT for COPD patients with PaO₂ ≤55 mmHg

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments																																																												
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes																																																													
Prospective																																																																					
Krop 1973 Stewart 1975 US	25.2 mo F/U (4 - 40)	Inclusion: COPD, PaO ₂ < 55 mmHg under optimal therapy, additional PaO ₂ decrease with treadmill exercise, relief of hypoxemia with 2 L/min O ₂ therapy	N=12 Male: 100% Age: 55 (33-64)	PaO ₂ 49±5.0 PaCO ₂ 44±6.9	FEV ₁ L 0.68±0.15	24	1y 8.3% 2y 33% (graph estimates)	<p><i>Survival</i> 56% at 2½ y</p> <p><i>Pulmonary function (n=11)</i> NS for PaCO₂, FVC, FEV₁</p> <p><i>Hospital days</i> ~30 days/patient before LTOT (n=11) ~20 days/patient 1 year after LTOT (n=10)</p> <p><i>Quality of life at 1 month</i></p> <table border="1"> <thead> <tr> <th></th> <th>—</th> <th>Post</th> <th></th> </tr> </thead> <tbody> <tr> <td>WAIS or W-B</td> <td></td> <td></td> <td></td> </tr> <tr> <td>FSIQ</td> <td>97.0</td> <td>103.1</td> <td>p<.05</td> </tr> <tr> <td>VIQ</td> <td>99.0</td> <td>103.3</td> <td>NS</td> </tr> <tr> <td>PIQ</td> <td>93.6</td> <td>102.0</td> <td>p<.01</td> </tr> <tr> <td>WMS</td> <td>97.8</td> <td>105.6</td> <td>p<.01</td> </tr> <tr> <td>B-G</td> <td>23.0</td> <td>9.2</td> <td>p<.01</td> </tr> <tr> <td>B₁₀</td> <td>24.8</td> <td>9.9</td> <td>p<.005</td> </tr> <tr> <td>FRT</td> <td>7.4</td> <td>7.5</td> <td>NS</td> </tr> <tr> <td>FT(T)</td> <td>29.4</td> <td>41.8</td> <td>p<.005</td> </tr> <tr> <td>MMPI</td> <td></td> <td></td> <td></td> </tr> <tr> <td>Depression</td> <td>24.9</td> <td>18.4</td> <td>p<.05</td> </tr> <tr> <td>Hypochondriasis</td> <td>20.7</td> <td>14.2</td> <td>p<.005</td> </tr> <tr> <td>Hysteria</td> <td>24.8</td> <td>17.4</td> <td>p<.025</td> </tr> <tr> <td>Social introversion</td> <td>27.5</td> <td>20.0</td> <td>p<.05</td> </tr> </tbody> </table> <p>Diaries - all report ADL improvement</p>		—	Post		WAIS or W-B				FSIQ	97.0	103.1	p<.05	VIQ	99.0	103.3	NS	PIQ	93.6	102.0	p<.01	WMS	97.8	105.6	p<.01	B-G	23.0	9.2	p<.01	B ₁₀	24.8	9.9	p<.005	FRT	7.4	7.5	NS	FT(T)	29.4	41.8	p<.005	MMPI				Depression	24.9	18.4	p<.05	Hypochondriasis	20.7	14.2	p<.005	Hysteria	24.8	17.4	p<.025	Social introversion	27.5	20.0	p<.05	VA patients, no patient lost to F/U
	—	Post																																																																			
WAIS or W-B																																																																					
FSIQ	97.0	103.1	p<.05																																																																		
VIQ	99.0	103.3	NS																																																																		
PIQ	93.6	102.0	p<.01																																																																		
WMS	97.8	105.6	p<.01																																																																		
B-G	23.0	9.2	p<.01																																																																		
B ₁₀	24.8	9.9	p<.005																																																																		
FRT	7.4	7.5	NS																																																																		
FT(T)	29.4	41.8	p<.005																																																																		
MMPI																																																																					
Depression	24.9	18.4	p<.05																																																																		
Hypochondriasis	20.7	14.2	p<.005																																																																		
Hysteria	24.8	17.4	p<.025																																																																		
Social introversion	27.5	20.0	p<.05																																																																		

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Ashutosh 1983 USA	2 y F/U	Inclusion: FEV ₁ < 2 SD predicted value and FEV ₁ /FVC% < 70%, right heart failure, mean PAP > 20 mmHg, pulmonary capillary wedge pressure < 15 mmHg Exclusion: left ventricular disease	Responders PAP: 37±12 N=17 Male: ND Age: 57	PaO ₂ 53±8 PaCO ₂ 46±9	FEV ₁ L 0.94±0.51	Prescribed > 18	2 y 13%	<i>Survival</i> Significant for responders (reduction in pulmonary hypertension) over non-responders, p<0.005	Significant change of PAP > or < 5 mmHg while breathing 28% O ₂ for 24 h used to divide patients into 2 groups; 1 withdrawal 2 withdrawals
			Non-responders PAP: 33±12 N=11 Male: ND Age: 60	PaO ₂ 54±12 PaCO ₂ 46±10	FEV ₁ L 0.83±0.58	Prescribed > 18	2 y 78%		

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Weitzenblum 1985 1991 France	11.5 y F/U, 44±30 mo of therapy (12-120)	Inclusion: history of chronic bronchitis, air- flow obstruction < 1.5 L, hypoxemia & PaO ₂ < 60 mmHg & clinically stable at 3 monthly measures, right heart failure or right ventricular hypertrophy, Ppa>20 mmHg, ≥ 1 y between catheterization before & after onset of LTOT, compliance (>15 h/d) Exclusion: left heart disease, systemic hypertension, chronic pulmonary or severe disease	N=24 Male: 92% Age: 59 (41-74)	PaO ₂ 52±6.5 PaCO ₂ 49±8.2	34±14	18	33 mo 25%* 73 mo 54% *Denominator= 16	<i>Hospital days per year (n=16)</i> Pre-LTOT 18±16 Post-LTOT 9±19 0.10 > p > 0.05 (NS) <i>Pulmonary function</i> FEV ₁ % 33±13 NS (compared with baseline) <i>Pulmonary arterial hypertension</i> Pre-LTOT 27 ±9.1 Post-LTOT 24±7.1 ns (compared to baseline)	Ambidirectional study, recruitment & consent given between 2 nd and 3 rd catheterization, no data on number of pts from onset of LTOT for mortality or dropouts before study enrollment

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Vergeret 1989 Denmark	1 y F/U	Inclusion: 40-75 y, severe COPD FEV ₁ /FVC<60%, total lung capacity >80% of reference values, FEV ₁ <1L & stable chronic respiratory insufficiency PaO ₂ <8kPa & >5.3kPa PaCO ₂ <8.2kPa Exclusion: pts on portable O ₂ , > 3 admissions	Fixed O ₂ N=75 Male: 84% Age: 63	PaO ₂ 54±7.5 PaCO ₂ ND	FEV ₁ L 0.8±7.4	14	1 y 12%	No significant clinical and functional differences between 2 groups.	8 withdrawals
			Portable O ₂ N=84 Male: 90% Age: 61			17	1 y 18%		5 withdrawals
Lahdensuo 1989 Finland	6 mo F/U	Inclusion: severe COPD, stable disease, PaO ₂ <55 or 55-59 & hematocrit > 55, cor pulmonale, or history of ≥1 acute cardiac failure from cor pulmonale Exclusion: smoking in the past 3 mo	N=26 Male: 73% Age: 63	PaO ₂ 49±6.7 PaCO ₂ 46±14	ND	Prescribed 24	ND	<i>Psychosocial response</i> BDI 18.2 vs 15.1 p<0.06 No significant changes were observed in any psychosocial measures including depression, general activity & independence, coping skills	---

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Dubois 1990 1994 Belgium	6 y	Inclusion: PaO ₂ <55 in controlled steady state ≥3 wks, PaCO ₂ did not increase "excessively" Exclusion: A severe disease that might be expected to influence short-term mortality. No patients has had previous LTOT	N=270 Male: 86% Age: 66	PaO ₂ 48±6 PaCO ₂ 47±9	30±12	18	1 y 30% 2 y 50% 3 y 57% 5 y 83%* 6 y 83%* *(graph estimates)		---
Strom 1991 1993 1998 Sweden	28 mo F/U (15-45)	Inclusion: Stable adults treated for chronic hypoxemia w/LTOT, approx 7.5 kPa, resting > 8 kPa, registered 1/1/87 – 6/30/89	N=405 Male: 50% Age: 67	PaO ₂ 50 PaCO ₂ 49	27±15	18	1 y 23% 2 y 44% 3 y 62% Severity subgroup (WHO score) <u>1 y</u> <u>2 y</u> S0 2% 32% S1 15% 30% S2 24% 51% S3-4 52% 81% (graph estimates)	<i>Hospitalizations</i> (no pre-post data) 44 days/year <i>Annual admissions</i> M 2.8±3.2 F 3.1±3.0 <i>Psychological impact</i> Negative impact on patient or patient/family caused by oxygen therapy, more common with gas cylinder or therapy > 16 h/d	Registry with no exclusion criteria for adults on LTOT, 60 withdrawals

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Gorecka 1992 Poland	1 y F/U	Inclusion: PaO ₂ ≤55 or 56-65 if one of following is present: Hct ≥55%, radiological signs of pulmonary arterial hypertension, ECG signs of right ventricular hypertrophy	N=315 Male: 74% Age: 62	PaO ₂ 51±8 PaCO ₂ 51±11	FEV ₁ L 0.79 ±0.31	>17	1 y 21%		12 regional centers, no patients lost to F/U
Dallari 1994 Italy	24 mo F/U (2-50)	Inclusion: COPD on LTOT from 1987-1992	N=166 Male: ND Age: 69	PaO ₂ 54±5.8 PaCO ₂ 51±7.6	36±11.3	16-20	2 y 22% 3 y 33%	<i>Predictors</i> Multivariate stepwise regression analysis showed that RVSP, age, and FEV ₁ were statistically significant independent predictors of survival.	---
Simonds 1995 England	1.6 y median for NIPPV (0.1-6.3) 5 y F/U	Inclusion: symptomatic, chronic hypercapnic respiratory failure unresponsive to O ₂ therapy, progressive deterioration in symptoms & arterial blood gas tensions	N=180 33 COPD Male: ND Age*: 57 *Subgroup data	PaO ₂ 46±6.0 PaCO ₂ 62±14	FEV ₁ L 0.58±0.3	7.88 Random subset of 16 which included other respiratory disorders, 48% COPD used supple- mental O ₂ therapy	1 y 15% 2 y 24% 3 y 32% 4 y 55% 5 y 55% (graph estimates)	<i>Pulmonary function</i> (n=30 COPD) NS for FEV ₁ <i>Sleep quality</i> * Very good 21% Average 67% Poor 5% <i>Adverse events</i> * Inconvenience (20) Nasal/mask problems (10) Gastric distension (3) Noise (3) *no baseline data, includes all diagnoses	Pts may have transitioned from other O ₂ therapy; NIPPV therapy started in hospital, 5 withdrawals

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Oswald-mannosser 1995 France	5 y (1-12 F/U)	Inclusion: COPD, FEV ₁ /VC ratio < 60%, TLC > 80% of predicted value Exclusion: Lung disease, (sequelae of pulmonary tuberculosis, pneumoconiosis), left heart disease, obesity (BMI > 32), sleep apnea, or other severe disease	N=84 Male: 89% Age: 63	PaO ₂ 52±5.4 PaCO ₂ 45±7.6	FEV ₁ L 0.8 (0.3)	>16	3 y 29% 5 y 52%	<i>Survival rate</i> PAP <25 mmHg vs. PAP ≥25 mmHg p<0.001 The level of PAP (together with age) is a good indicator of survival in COPD patients receiving LTOT	---
Borak 1996 Poland	1 y F/U	Inclusion: PaO ₂ < 55 mmHg, or 55-65 if polycythemic	N=124 Male 68% Age: 56 (28-76)	PaO ₂ 55±6.2 PaCO ₂ 47±8.2	FEV ₁ L 0.88±0.44	15	27%	<i>Psychological impact (n=90)</i> Significant improvement, p<0.001, for: Bourdon-Wiersma Test – correct deletion Rey test remembered words Depression Anxiety Psychological tension General mood Self-esteem Attitude towards therapy, future & life goals Tests include VRT, MAS, Beck's Depression Scale, SOPER)	All baseline data for survivors only n=90, no patients lost to F/U

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Lin 1996 Taiwan	2 weeks of therapy	Inclusion: stable hypercapnia, PaO ₂ ≥ 44 mmHg, FEV ₁ P < 70%, FEV ₁ /FVC < 70%, FEV ₁ /FVC < 50% predicted, PaO ₂ < 55 mmHg, or PaO ₂ > 55-60 right heart failure & polycythemia Exclusion: sleep apnea with hypopnea index ≥ 10, > 15% increase in FEV ₁ , CNS, neuromuscular, CHF, endocrine, renal, or unstable disorders < 1 mo	N=12 Male: 58% Age: 65	PaO ₂ 52 ± 2.5 PaCO ₂ 51 ± 3.5	ND	24		<i>Sleep stages/efficiency*</i> NS for the following (compared to baseline): Sleep efficiency Sleep latency Arousal index Movement index Snore index Total sleep time Stage 1 through 4 REM *All therapy in hospital	No patients lost to F/U
Cini 1996 Italy	18 mo of therapy	Inclusion: COPD on LTOT ≥ 18 months, chronic hypercapnia, PaCO ₂ > 50, ≥ one hospital admission due to severe exacerbation in past 18 months Exclusion: ≥ 15% increase FEV ₁	LTOT N=17 Male: 53% Age: 67	PaO ₂ 50 ± 4.5 PaCO ₂ 48 ± 6.8	33 ± 10	>8 nightly	18 mo 18%	<i>Pulmonary function at 18 months</i> FEV ₁ % (compared with baseline) LTOT 32 ± 13 NS Historical LTOT 28 ± 13 NS <i>Hospital admission</i> Comparison to 18 months prior to the study LTOT 2.0 ± 0.7 vs 1.0 ± 0.9 p < 0.005 Historical LTOT 1.5 ± 0.7 vs 1.5 ± 1.1 NS <i>Days in hospital</i> Comparison to 18 months prior to the study LTOT 55 ± 23 vs 18 ± 20 p < 0.005 Historical LTOT 47 ± 25 vs 38 ± 29 NS	Retrospective, historical controls, no patients lost to F/U
			Historical LTOT N=29 Male: 53% Age: 66	PaO ₂ 54 ± 6.8 PaCO ₂ 51 ± 4.5	31 ± 12	ND	18 mo 17%		

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Okubadejo 1996 UK	6 mo of therapy	Inclusion: COPD FEV ₁ <1.5L, PaO ₂ <7.3 when stable or a PaO ₂ <8.0 with evidence of cor pulmonale & ECG changes Exclusion: age <45, COPD exacerbation within past 3 wk	N=23 Male: 35% Age: 71 Median (47-82)	PaO ₂ 53± 6.0 PaCO ₂ 50± 9.0	40±17	17	6 mo 17%	<i>Pulmonary function (n=19)</i> FEV ₁ % Predicted 38±17 <i>Quality of life (n=19)</i> SGRQ Total NS SIP NS	Baseline data for 19 survivors only, no patients lost to F/U
Heaney 1997 N Ireland	> 8 y study period	Inclusion: period 9/86-4/89, lifestyle or work severely limited, PaO ₂ < 6 kPa, no smoking; period > 4/89 FEV ₁ <1.51 L /FVC < 2.01, PaO ₂ < 7.3 kPa, PaCO ₂ > 6 kPa, edema, clinically stable, optimized therapy	N=178 Male: 62% Age: 64	PaO ₂ 49 PaCO ₂ 49	FEV ₁ L 0.93	10-15 (17%) > 15 (64%)	10 mo 31% 20 mo 50% 60 mo 67%		Ambidirectional F/U, no patients lost to F/U
Aida 1998 Japan	Ambi-directional 6 y, mean F/U 2.4 y	Inclusion: LTOT patients registered between 7/85 – 6/93, COPD, 40-80 y, PaO ₂ ≤ 60 mmHg - room air at rest, O ₂ > 15h/d	N=4,552 466 COPD Male*: 73% Age*: 69 *Subgroup data	PaO ₂ 50.3 PaCO ₂ 49	ND	> 15	1 y 12.1% 2 y 37.9% 5 y 60.5%		1,740 institutions in registry, diagnosed by individual physician, overlapping population with Miyamoto 1995

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Zielinski 1998 Poland	6 y	Inclusion: stable hypoxemia (PaO ₂ < 55) assessed at steady state PaO ₂ =56 to 65	N=95 Male: 76% Age: 58	PaO ₂ 55± 6 PaCO ₂ 48 ± 9	FEV ₁ L 0.84±0.3	14	2 y 23%	"LTOT for 14 to 15h/d resulted in a long-term stabilization of pulmonary hypertension" 19 patients completed 6 years of LTOT	---
Hjalmsen 1999b Sweden	3 mo	Inclusion: stable PaO ₂ ≤ 7.3 kPa or ≤8.0 kPa with coexisting polycythemia or cor pulmonale Exclusion: history of cardiac or cerebrovascular disease, history of psychiatric disorder by DSM-IV, metabolic or endocrine disorder, condition may influence cognitive performance	N=10 Male: 40% Age: 66 (51-74)	PaO ₂ 50±8.3 PaCO ₂ 53±11	38±12	18-24	ND	<i>Neuropsychological assessment</i> No significant changes comparing baseline and 3 months after LTOT for the following: Trail Making Test Seashore Rhythm Test WMS-R CalCAP Grooved Pegboard STMS	No patients lost to F/U

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Farrero 2001 Spain	1 y F/U	Inclusion: primary COPD requiring LTOT, history of ≥6 mo LTOT, resides near hospital	N=62 Male: ND Age: 68	PaO ₂ 50±7 PaCO ₂ 56±8	27±9	ND	1 y 34%	<i>Emergency room visits (n=48, change over 1 y F/U)</i> -1.6±2.0 <i>Hospital admission rate (n=48)</i> -1.3±1.7 <i>Hospital stay (n=48)</i> -18±25 <i>Quality of life (n=16)</i> NS for Chronic Respiratory Questionnaire <i>Pulmonary function (n=48)</i> Pre Post FEV ₁ % 27±8 24±6 p=0.01	No patients lost to F/U
Sergi 2002 Basel	42 mo	Inclusion: stable PaO ₂ >60, FEV ₁ < 60% predicted & FEV ₁ /VC<70% with TLC >80% predicted Exclusion: asthma, bronchiectasis, interstitial lung, heart disease, other serious disorder, hepatic cirrhosis or chronic renal failure	N=10 Male: ND Age: 66	PaO ₂ 63±2.3 PaCO ₂ 44±2.3 See comments	40±3.4	>18	ND	<i>Pulmonary function</i> FEV ₁ % 34±2.2 p<0.05 Data compared to baseline, not at start of LTOT. 9 were desaturators	Of 52 enrolled, 10 developed chronic respiratory failure requiring LTOT (PaO ₂ <55), no ABG data reported at start of LTOT, LTOT started at 22±6.8 mo (median, 12-36 m) after enrollment
Bratel 2003 Sweden	6.2±0.9 mo F/U	Inclusion: Moderate to severe airway obstruction <70% predicted, FEV ₁ /VC<65%	N=12 Male: ND Age: 69 (n=19)	PaO ₂ 55±8 PaCO ₂ 44±6.7	29±18	≥ 16 (n=11)	ND	<i>Pulmonary function</i> FEV ₁ % 28±17 ns compared to baseline	No patients lost to F/U

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Retrospective									
McKeon 1987 Australia	14 y F/U	Inclusion: LTOT guidelines established Oct 1982: COPD, right ventricular hypertrophy, secondary polycythemia, PaO ₂ < 56 mmHg & recurrent right heart failure; Prior to Oct 1982: LTOT qualification by means test	N=84 Male: ND Age: ND	ND	ND	ND	1 y 6% 2 y 20% 5 y 64%	---	Most pts already on LTOT at initiation of study, no patients lost to F/U
Corrado 1994 Italy	4 y F/U	Inclusion: COPD with chronic respiratory insufficiency admitted 1984- 1986 for acute respiratory failure	N=35 Male: 74% Age: 66	PaO ₂ 52±5.7 PaCO ₂ 54±6.9	24±9.9	>15 (15-18)	1 y 6% 2 y 17% 3 y 37% 4 y 49% (graph estimates)	"LTOT of more than 15h/d seems to improve survival for at least 2 to 4 years."	Baseline data at discharge, no patients lost to F/U

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Buyse 1995 Belgium	3 y F/U	Inclusion: adults with stable disease prescribed LTOT on 7/1/84 – 7/31/92	COPD N=49 Male*: 77% Age*: 62 *Multiple diseases N=83	PaO ₂ 50±7 PaCO ₂ 48±10 (n=46)	33±17 Multiple diseases N=83	ND	1 y 13% 2 y 40% (n=15)	---	27% of sample had PaO ₂ 55-60
Miyamoto 1995 Japan	7 y	Inclusion: LTOT pts registered between 7/85 – 6/93, PaO ₂ ≤ 55 mmHg - room air at rest, or ≤ 60 w/pulmonary hypertension or severe hypoxemia (≤ 55) during exercise or sleep Exclusion: PaO ₂ > 60 mmHg, FEV ₁ /FVC > 70%	N=5,055 Male: 75% Age: 70	PaO ₂ M 51±6.9 F 49±7.3 PaCO ₂ M 48±10 F 51±9.4	ND	ND	1 y 13% 2 y 25% 3 y 36% 5 y 58%	<i>Survival</i> M 4.8±9.9 vs F 5.28±0.18 p<0.05 NS for length of oxygen inhalation between sexes for LTOT pts > 15 h/d, n=unknown Significant (p<.05) difference between sexes for baseline PaO ₂ & PaCO ₂ values	1,740 institutions in registry, diagnosed by individual physician, overlapping population with Aida 1998
Chailleux 1996 2003 France	10 y	Inclusion: LTOT patients PaO ₂ ≤ 55 & >15h oxygen treated 1/1984 -12/1992	N=12,403 Chronic bronchitis 1,755 Asthma 551 Emphysema 1,556 Male: 84% Age: 69	PaO ₂ M 53±7.5 F 53±7.2 PaCO ₂ M 47± 8.6 F 48± 8.3	M 35±15 F 41±18	ND	1 y 25% 2 y 41% 5 y 70% (graph estimates)	In COPD: male sex, older age, lower BMI, FEV1% predicted, PaO ₂ and PaCO ₂ are independent negative prognostic factors for survival rate. Survival is slightly better for patients with bronchitis & asthma with permanent dyspnea and worse for those with emphysema	

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Hjalmarsen 1999a Sweden	8 y F/U	Inclusion: PaO ₂ ≤ 7.3 kPa, LTOT following international prescription guidelines Exclusion: Interstitial pulmonary fibrosis, cancer, left heart failure	N=76 Male: 50% Age: 67	PaO ₂ 48±0.75 (n=67) PaCO ₂ 53±1.5 (n=66)	34±1.7 (n=59)	Prescribed >15	2 y 27% 5 y 50%	<i>Survival</i> <u>2 y</u> <u>5 y</u> M 56% 30% F 83% 60% p<0.005	1 withdrawal
Crockett 2001 Australia	10 y F/U	Inclusion: Patients with chronic airflow limitation with LTOT between 1977 and 1999 Exclusion: asthma	N=505 Male: 49% Age: 70	PaO ₂ M 53± 8.1 F 50.9±8.1 PaCO ₂ M 48±10 F 50±8.5	FEV ₁ L M: 0.86±0.45 F: 0.65±0.25	Prescribed > 15 for Belgian, Prescribed mean 19 for Swedish	1 y 25% 2 y 49% 5 y 81% 10 y 99%	---	---
Ringbaek 2002 Denmark	10 mo of therapy	Inclusion: COPD hypoxaemic patients from Danish Oxygen Registry	Total N=246 COT Male: 57% Age: 68 ----- NCOT Male: 49% Age: 72	PaO ₂ 48±5.3 PaCO ₂ 51±9.0 ----- PaO ₂ 48±6.8 PaCO ₂ 49±11	30±11 (n=114)	≥15 ----- < 15	ND	<i>Hospitalization</i> Post Days 23.7±24.5 13.4± 22.7 p<0.001 Admission 2.1±1.9 1.6±2.2 p<0.001 Hospital day were reduced by 23.8%, 43.5% and 51.2% LTOT is associated with a reduction in hospitalization, ns between groups	---

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Demirel 2003 Turkey	17±15 mo (1-71) of therapy	Inclusion: Patients received COT COPD by ATS with ABG data	N=127 124 COPD (97%) Male: 73% Age: 62	PaO ₂ 52± 11 PaCO ₂ 50±9.6	31±12	12 (11%) > 15 (43%)	5.5% F/U interval unknown	77% patients stated that they had benefited from therapy. “Continuous oxygen therapy is an effective treatment modality but patient compliance remains a problem”	ABG data analyzed for 86 patients, 6 centers, 7 lost to F/U

Evidence Table 4. Cohort studies of LTOT for COPD patients with PaO₂ between 56 and 59 mmHg

Study Year Country	Study design		Population	Baseline		O ₂ therapy: hours/day	Outcomes		Comments
	Duration	Inclusion / exclusion		PaO ₂ PaCO ₂ mmHg	FEV ₁ (% Predicted)		Mortality	Other outcomes	
Prospective									
Sliwinski 1992 1993 Poland	2 y of therapy	Inclusion: PaO ₂ < 55 mmHg, or PaO ₂ 55-65 with pulmonary hypertension, right ventricular hypertrophy, elevated hematocrit Exclusion: conditions influencing survival (sys hypertension, IHD, left heart failure, liver cirrhosis, renal failure, DM, cancer)	N=46 Male: 83% Age: 55	PaO ₂ 57±6 PaCO ₂ 48±9	FEV ₁ L 0.84±0.32	15	1 y 8.7% 2 y 33%	<i>Pulmonary function</i> FEV ₁ 0.7±0.3 p<0.01 (compare with baseline at 2 y, n=19)	---
Sandek 2001 Sweden	6 mo F/U	Inclusion: irreversible airflow obstruction FEV ₁ %P < 70 & FEV ₁ /FVC ratio <70%, 2 PaO ₂ measures < 7.3 kPa (3 wk apart) or 7.3-7.9 w/chronic right heart insufficiency	N=14 Male: ND Age: 69 (45-74)	PaO ₂ 58 (46-63) PaCO ₂ 41 (30-49) Median	34 Median (17-68)	16	ND	<i>Pulmonary function</i> FEV ₁ % 32 (14-66) Median	Data inconsistent, statistical methods used inappropriate for data, no patients lost to F/U
Retrospective									
Hjalmarsen 1999a Sweden	8 y F/U	Inclusion: PaO ₂ ≥ 7.4 kPa, LTOT following international prescription guidelines Exclusion: Interstitial pulmonary fibrosis, cancer, left heart failure	N=48 Male: 79% Age: 69	PaO ₂ 62±0.75 PaCO ₂ 44±1.5	33±2.0 (SE) (n=43)	Prescribed >15	24 mo 22% 60 mo 60%	<i>Survival</i> 50% survival: Male 4.2 y Female 5.1 y	1 withdrawal

Reject List

1. Abdulla J, Godtfredsen N, Pisinger C, Wennike P, Tonnesen P. Adequacy of oxygenation in a group of Danish patients with COPD on long-term oxygen therapy. *Monaldi Archives for Chest Disease* 2000; 55(4):279-282. **No baseline data**
2. Ambrosino N, Clini E. Noninvasive ventilation in COPD patients with chronic respiratory failure--pro. *Monaldi Archives for Chest Disease* 2000; 55(1):54-57. **Review/report**
3. Andersson I, Johansson K, Larsson S, Pehrsson K. Long-term oxygen therapy and quality of life in elderly patients hospitalised due to severe exacerbation of COPD. A 1 year follow-up study. *Respiratory Medicine* 2002; 96(11):944-949. **QOL not stratified by tx / non_tx groups**
4. Anon JM, Garcia dL, Zarazaga A, GomezTello V, Garrido G. Mechanical ventilation of patients on long-term oxygen therapy with acute exacerbations of chronic obstructive pulmonary disease: prognosis and cost-utility analysis. *Intensive Care Med* 1999;25:452-7. **Not population of interest**
5. Bellone A, Venanzi D, De Angelis G, Adone R, Aliprandi P, Castelli C et al. Who should prescribe long-term oxygen in patients affected by chronic arterial hypoxaemia? *Monaldi Archives for Chest Disease* 1994; 49(5):396-398. **No outcomes of interest**
6. Berg J. Quality of life in COPD patients using transtracheal oxygen. *MEDSURG Nursing* 1996; 5(1):36-40. **n<10, no outcomes of interest**
7. Birnbaum ML, Cree EM, Rasmussen H, Lewis P, Curtis JK. Effects of intermittent positive pressure breathing on emphysematous patients. *American Journal of Medicine* 1966; 41(4):552-561. **Not LTOT**
8. Bloom BS, Daniel JM, Wiseman M, Knorr RS, Cebul R, Kissick WL. Transtracheal oxygen delivery and patients with chronic obstructive pulmonary disease. *Respiratory Medicine* 1989; 83(4):281-288. **Not LTOT, comparison of delivery methods**

9. Bonsignore G. Nocturnal desaturation in patients with bronchitis and emphysema. *European Journal of Respiratory Diseases - Supplement* 1983; 126:291-294. **Not LTOT**
10. Booth S, Anderson H, Swannick M, Wade R, Kite S, Johnson M et al. The use of oxygen in the palliation of breathlessness. A report of the expert working group of the Scientific Committee of the Association of Palliative Medicine. *Respiratory Medicine* 98(1):66-77, 2004.
Guideline/report
11. Borak J, Sliwinski P, Piasecki Z, Zielinski J. Psychological status of COPD patients on long term oxygen therapy. *European Respiratory Journal* 1991; 4(1):59-62. **No baseline data**
12. Boysen PG. Nocturnal oxygen therapy and hemodynamic changes in COPD. *Chest* 1984; 85(1):2-3. **Report/abstract**
13. Brambilla I, Arlati S, Micallef E, Sacerdoti C, Rolo J. A portable oxygen system corrects hypoxemia without significantly increasing metabolic demands. *American Review of Respiratory Disease* 1985; 131(1):51-53. **n<10**
14. Burns HL, Ralston D, Muller M, Pegg S. Cooking and oxygen. An explosive recipe. *Australian Family Physician* 2001; 30(2):138-140.
Case report, not relevant
15. Calverley PM, Leggett RJ, McElderry L, Flenley DC. Cigarette smoking and secondary polycythemia in hypoxic cor pulmonale. *American Review of Respiratory Disease* 1982; 125(5):507-510.
n<10
16. Cano NJ, Roth H, CourtOrtune I, Cynober L, GerardBoncompain M, Cuvelier A et al. Nutritional depletion in patients on long-term oxygen therapy and/or home mechanical ventilation. *European Respiratory Journal* 2002; 20(1):30-37. **No outcome of interest**
17. Carter R, Tashkin D, Djahed B, Hathaway E, Nicotra MB, Tiep BL. Demand oxygen delivery for patients with restrictive lung disease. *Chest* 1989; 96(6):1307-1311. **n<10 per arm**
18. Casanova C, Celli BR, Tost L, Soriano E, Abreu J, Velasco V et al. Long-term controlled trial of nocturnal nasal positive pressure

- ventilation in patients with severe COPD.[see comment]. *Chest* 2000; 118(6):1582-1590. **Not population of interest, Not LTOT**
19. Chaouat A, Weitzenblum E, Kessler R, Schott R, Charpentier C, LeviValensi P et al. Outcome of COPD patients with mild daytime hypoxaemia with or without sleep-related oxygen desaturation. *European Respiratory Journal* 2001; 17(5):848-855. **Not LTOT, n<10**
 20. Chiang LL, Hung TC, Ho SC, Lin HC, Yu CT, Wang CH et al. Respiratory response to carbon dioxide stimulation during low flow supplemental oxygen therapy in chronic obstructive pulmonary disease. *Journal of the Formosan Medical Association* 2002; 101(9):607-615. **Not LTOT**
 21. Cornford CS. Lay beliefs of patients using domiciliary oxygen: a qualitative study from general practice. *British Journal of General Practice* 2000; 50(459):791-793. **Qualitative research**
 22. Corriveau ML, Rosen BJ, Dolan GF. Oxygen transport and oxygen consumption during supplemental oxygen administration in patients with chronic obstructive pulmonary disease. *American Journal of Medicine* 1989; 87(6):633-637. **Not LTOT**
 23. Crockett AJ, Cranston JM, Moss JR, Alpers JH. A review of long-term oxygen therapy for chronic obstructive pulmonary disease. *Respiratory Medicine* 2001; 95(6):437-443. **Review**
 24. Dal Nogare AR, Rubin LJ. The effects of hydralazine on exercise capacity in pulmonary hypertension secondary to chronic obstructive pulmonary disease. *American Review of Respiratory Disease* 1986; 133(3):385-389. **Not LTOT**
 25. Damato S, Frigo V, Dell'Oca M, Negretto GG, Tarsia P. Utility of monitoring breathing during night hours in COPD patients undergoing long-term oxygen therapy. *Monaldi Archives for Chest Disease* 1997; 52(2):106-111 **Not LTOT, no outcomes of interest**
 26. Dardes N, Chiappini MG, Moscatelli B, Re MA, Pellicciotti L, Benedetti G et al. Quality of life of COPD patients treated by long-term oxygen. *Lung* 1990; 168:Suppl-93. **No baseline data**

27. De Angelis G, Sposato B, Mazzei L, Giocondi F, Sbrocca A, Propati A et al. Predictive indexes of nocturnal desaturation in COPD patients not treated with long term oxygen therapy. *European Review for Medical & Pharmacological Sciences* 2001; 5(5-6):173-179. **not LTOT**
28. Domingo C, Roig J, Coll R, Klamburg J, Izquierdo J, RuizManzano J et al. Evaluation of the use of three different devices for nocturnal oxygen therapy in COPD patients. *Respiration* 1996; 63(4):230-235. **No outcome of interest**
29. DomingoSalvany A, Lamarca R, Ferrer M, GarciaAymerich J, Alonso J, Felez M et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. *American Journal of Respiratory & Critical Care Medicine* 2002; 166(5):680-685. **Not LTOT**
30. Earnest MA. Explaining adherence to supplemental oxygen therapy: the patient's perspective. *Journal of General Internal Medicine* 2002; 17(10):749-755. **No baseline data**
31. Eaton T, Garrett JE, Young P, Fergusson W, Kolbe J, Rudkin S et al. Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. *European Respiratory Journal* 2002; 20(2):306-312. **Not population of interest**
32. Eldridge F, Gherman C. Studies of oxygen administration in respiratory failure. *Annals of Internal Medicine* 1968; 68(3):569-578. **Not LTOT**
33. Elliott MW, Mulvey DA, Moxham J, Green M, Branthwaite MA. Domiciliary nocturnal nasal intermittent positive pressure ventilation in COPD: mechanisms underlying changes in arterial blood gas tensions. *European Respiratory Journal* 1991; 4(9):1044-1052. **n< 10**
34. Elliott MW. Noninvasive ventilation in COPD patients with chronic respiratory failure--con. *Monaldi Archives for Chest Disease* 2000; 55(1):58-61. **Review**
35. Estopa RM, Monasterio C, Escarrabill J. Daily life desaturations in COPD patients on LTOT: International Oxygen Club multicentre

- European study. *Monaldi Archives for Chest Disease* 1993; 48(5):426-428. **No outcomes of interest**
36. Fairshter RD, Wilson AF. Nonpharmacologic treatment of chronic obstructive pulmonary disease. *Comprehensive Therapy* 1982; 8(9):35-41. **Review**
 37. Faulkner MA, Hilleman DE. The economic impact of chronic obstructive pulmonary disease. *Expert Opinion on Pharmacotherapy* 2002; 3(3):219-228. **Review**
 38. Findley LJ, Whelan DM, Moser KM. Long-term oxygen therapy in COPD. *Chest* 1983; 83(4):671-674. **Review**
 39. Flenley DC, Calverly PM, Douglas NJ, Catterall JR, Lamb D, Brezinova V. Nocturnal hypoxemia and long-term domiciliary oxygen therapy in "blue and bloated" bronchitics. Physiopathologic correlations. *Chest* 1980; 77(2:Suppl):Suppl-7. **No outcomes of interest**
 40. Fletcher EC, Levin DC. Cardiopulmonary hemodynamics during sleep in subjects with chronic obstructive pulmonary disease. The effect of short- and long-term oxygen. *Chest* 1984; 85(1):6-14. **n < 10**
 41. Fletcher EC, Lockett RA, GoodnightWhite S, Miller CC, Qian W, CostarangosGalarza C. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO₂ above 60 mm Hg. *American Review of Respiratory Disease* 1992; 145(5):1070-1076. **Not population of interest**
 42. Fletcher EC, Donner CF, Midgren B, Zielinski J, LeviValensi P, Braghiroli A et al. Survival in COPD patients with a daytime PaO₂ greater than 60 mm Hg with and without nocturnal oxyhemoglobin desaturation. *Chest* 1992; 101(3):649-655. **Data not stratified by tx / non_tx groups**
 43. Foucher P, Baudouin N, Merati M, Pitard A, Bonniaud P, ReybetDegat O et al. Relative survival analysis of 252 patients with COPD receiving long-term oxygen therapy. *Chest* 1998; 113(6):1580-1587. **Subset of Chailleux 2003**

44. Fujimoto K, Matsuzawa Y, Yamaguchi S, Koizumi T, Kubo K. Benefits of oxygen on exercise performance and pulmonary hemodynamics in patients with COPD with mild hypoxemia. *Chest* 2002; 122(2):457-463. **Not LTOT**
45. Fussell KM, Ayo DS, Branca P, Rogers JT, Rodriguez M, Light RW. Assessing need for long-term oxygen therapy: a comparison of conventional evaluation and measures of ambulatory oximetry monitoring. *Respiratory Care* 2003; 48(2):115-119. **No outcomes of interest**
46. Gajanan G. Long term domiciliary oxygen therapy in chronic obstructive pulmonary disease. *National Medical Journal of India* 1993; 6(5):219-220. **Report**
47. Garrod R, Bestall JC, Paul E, Wedzicha JA. Evaluation of pulsed dose oxygen delivery during exercise in patients with severe chronic obstructive pulmonary disease.[see comment]. *Thorax* 1999; 54(3):242-244. **n <10**
48. Garrod R, Paul EA, Wedzicha JA. Supplemental oxygen during pulmonary rehabilitation in patients with COPD with exercise hypoxaemia.[see comment]. *Thorax* 2000; 55(7):539-543. **Not LTOT**
49. Garrod R, Mikelsons C, Paul EA, Wedzicha JA. Randomized controlled trial of domiciliary noninvasive positive pressure ventilation and physical training in severe chronic obstructive pulmonary disease. *American Journal of Respiratory & Critical Care Medicine* 2000; 162(4:Pt 1):t-41. **Mean PaO2 > 65 & no LTOT**
50. Gibbons D, Conneely J, Smith J. An audit of provision of long-term oxygen therapy for COPD patients. *Professional Nurse* 2002; 18(2):107-110. **Report/audit**
51. Hanson CW, III, Marshall BE, Frasch HF, Marshall C. Causes of hypercarbia with oxygen therapy in patients with chronic obstructive pulmonary disease. *Critical Care Medicine* 1996; 24(1):23-28. **Study of computer model with use of pt data**
52. Hjalmsen A, Aasebo U, Aleksandersen G, Jorde R. Cardiovascular responses to tests for autonomic dysfunction in patients with chronic obstructive pulmonary disease with and without continuous long-term

- oxygen therapy. *Journal of the Autonomic Nervous System* 1996; 60(3):169-174. **No outcomes of interest, N<10**
53. Hoang Thi TH, Guillemin F, Cornette A, Polu JM, Briancon S. Health-related quality of life in long-term oxygen-treated chronic obstructive pulmonary disease patients. *Lung* 1997; 175(1):63-71. **No outcomes of interest**
 54. Hoffman LA, Dauber JH, Ferson PF, Openbrier DR, Zullo TG. Patient response to transtracheal oxygen delivery. *American Review of Respiratory Disease* 1987; 135(1):153-156. **Evaluation of transtrachial oxygen**
 55. Hoffman LA, Johnson JT, Wesmiller SW, Scirba FC, Ferson PF, Mazzocco MC et al. Transtracheal delivery of oxygen: efficacy and safety for long-term continuous therapy. *Annals of Otology, Rhinology & Laryngology* 1991; 100(2):108-115. **Evaluation of TT method**
 56. Hoffman LA, Wesmiller SW, Scirba FC, Johnson JT, Ferson PF, Zullo TG et al. Nasal cannula and transtracheal oxygen delivery. A comparison of patient response after 6 months of each technique. *American Review of Respiratory Disease* 1992; 145(4:Pt 1):t-31. **No baseline data**
 57. Ibanez M, Aguilar JJ, Maderal MA, Prats E, Farrero E, Font A et al. Sexuality in chronic respiratory failure: coincidences and divergences between patient and primary caregiver. *Respiratory Medicine* 2001; 95(12):975-979. **No baseline data**
 58. Jakobsson P, Jorfeldt L. Long-term oxygen therapy may improve skeletal muscle metabolism in advanced chronic obstructive pulmonary disease patients with chronic hypoxaemia. *Respiratory Medicine* 1995; 89(7):471-476. **n < 10**
 59. Jones SE, Packham S, Hebden M, Smith AP. Domiciliary nocturnal intermittent positive pressure ventilation in patients with respiratory failure due to severe COPD: long-term follow up and effect on survival.[see comment]. *Thorax* 1998; 53(6):495-498. **Not LTOT**
 60. Kampelmacher MJ, van Kestern RG, Alsbach GP, Melissant CF, Wynne HJ, Douze JM et al. Characteristics and complaints of

- patients prescribed long-term oxygen therapy in The Netherlands. *Respiratory Medicine* 1998; 92(1):70-75. **Not population of interest**
61. Kampelmacher MJ, Van Kesteren RG, Alsbach GP, Melissant CF, Wynne HJ, Douze JM et al. Prescription and usage of long-term oxygen therapy in patients with chronic obstructive pulmonary disease in The Netherlands. *Respiratory Medicine* 1999; 93(1):46-51. **No baseline data**
 62. Kampelmacher MJ, van Kestern RG, Alsbach GP, Melissant CF, Wynne HJ, Douze JM et al. Characteristics and complaints of patients prescribed long-term oxygen therapy in The Netherlands. *Respir Med* 1998; 92:70-5. **No outcomes of interest**
 63. Katsura H, Ogata M, Kida K. Factors determining outcome in elderly patients with severe COPD on long-term domiciliary oxygen therapy. *Monaldi Archives for Chest Disease* 2001; 56(3):195-201. **Not population of interest**
 64. Lareau S. The effect of positive-pressure breathing on the arterial oxygen tension in patients with chronic obstructive pulmonary disease receiving oxygen therapy. *Heart & Lung: Journal of Acute & Critical Care* 1976; 5(3):449-452. **Not LTOT**
 65. Lefcoe N, Carter P. Intermittent positive-pressure breathing in chronic obstructive pulmonary disease. *Canadian Medical Association Journal* 1970; 103(3):279-281. **Not LTOT**
 66. LeviValensi P, Weitzenblum E, Pedinielli JL, Racineux JL, Duwoos H. Three-month follow-up of arterial blood gas determinations in candidates for long-term oxygen therapy. A multicentric study. *American Review of Respiratory Disease* 1986; 133(4):547-551. **No outcomes of interest**
 67. LeviValensi P, Jounieaux V, Aubry P, Rose D, Aouine H, Rida Z. Sleep disorders and oxygen therapy in chronic bronchitis-emphysema. *European Respiratory Journal - Supplement* 1990; 11:519s-522s. **Not LTOT**
 68. LeviValensi P, Weitzenblum E, Rida Z, Aubry P, Braghiroli A, Donner C et al. Sleep-related oxygen desaturation and daytime pulmonary haemodynamics in COPD patients.[erratum appears in *Eur Respir J*

- 1992 May;5(5):645]. *European Respiratory Journal* 1992; 5(3):301-307. **Not LTOT**
69. LeviValensi P, Aubry P, Rida Z. Nocturnal hypoxemia and long-term oxygen therapy in COPD patients with daytime PaO₂ 60-70 mmHg. *Lung* 1990; 168:Suppl-5. **Protocol only, no data**
 70. Little SA, Elkholy MM, Chalmers GW, Farouk A, Patel KR, Thomson NC. Predictors of nocturnal oxygen desaturation in patients with COPD. *Respiratory Medicine* 1999; 93(3):202-207. **Not LTOT**
 71. MacNee W. Predictors of survival in patients treated with long-term oxygen therapy. *Respiration* 1992; 59:Suppl-7. **Commentary/review**
 72. Malik SK. Oxygen therapy in chronic obstructive pulmonary disease. *Indian J Chest Dis* 1969;11:186-95. **No outcomes of interest**
 73. McDermott SC. Use of a wheelchair oxygen walker in exercise and rehabilitation of patients with chronic obstructive pulmonary disease. *Respiratory Care* 1977; 22(11):1222-1225. **Not LTOT**
 74. McDonald CF, Blyth CM, Lazarus MD, Marschner I, Barter CE. Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia. *American Journal of Respiratory & Critical Care Medicine* 1995; 152(5:Pt 1):t-9. **Not population of interest**
 75. Meecham Jones DJ, Paul EA, Jones PW, Wedzicha JA. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. *American Journal of Respiratory & Critical Care Medicine* 1995; 152(2):538-544. **Primary to evaluate nPPV, pts had LTOT at baseline**
 76. Montner P, Sergent M, Case E, Douglas M, Griego E, Martinez F et al. TQI in the Albuquerque Veterans Affairs Medical Center's long-term oxygen therapy program. *Joint Commission Journal on Quality Improvement* 1998; 24(4):203-211. **Not LTOT**
 77. Morrison D, Skwarski K, MacNee W. Review of the prescription of domiciliary long term oxygen therapy in Scotland.[erratum appears in *Thorax* 1995 Dec;50(12):1327]. *Thorax* 1995; 50(10):1103-1105. **No outcomes of interest**

78. Morrison D, Skwarski KM, MacNee W. The adequacy of oxygenation in patients with hypoxic chronic obstructive pulmonary disease treated with long-term domiciliary oxygen.[erratum appears in *Respir Med* 1997 Aug;91(7):442]. *Respiratory Medicine* 1997; 91(5):287-291. **No outcomes of interest**
79. Murata GH, Gorby MS, Kapsner CO, Chick TW, Halperin AK. A multivariate model for the prediction of relapse after outpatient treatment of decompensated chronic obstructive pulmonary disease. *Archives of Internal Medicine* 1992; 152(1):73-77. **Not LTOT**
80. O'Donohue WJ, Jr. Effect of oxygen therapy on increasing arterial oxygen tension in hypoxemic patients with stable chronic obstructive pulmonary disease while breathing ambient air. *Chest* 1991; 100(4):968-972. **No outcomes of interest**
81. Oba Y, Salzman GA, Willsie SK. Reevaluation of continuous oxygen therapy after initial prescription in patients with chronic obstructive pulmonary disease.[see comment]. *Respiratory Care* 2000; 45(4):401-406. **No outcomes of interest**
82. Okubadejo AA, Paul EA, Wedzicha JA. Domiciliary oxygen cylinders: indications, prescription and usage. *Respiratory Medicine* 1994; 88(10):777-785. **No LTOT**
83. Okubadejo AA, O'Shea L, Jones PW, Wedzicha JA. Home assessment of activities of daily living in patients with severe chronic obstructive pulmonary disease on long-term oxygen therapy. *European Respiratory Journal* 1997; 10(7):1572-1575. **No baseline, enrollment criteria includes pts already on LTOT**
84. PelletierFleury N, Lanoe JL, Fleury B, Fardeau M. The cost of treating COPD patients with long-term oxygen therapy in a French population. *Chest* 1996; 110(2):411-416. **Cost analysis**
85. Pepin JL, Barjhoux CE, Deschaux C, Brambilla C. Long-term oxygen therapy at home. Compliance with medical prescription and effective use of therapy. ANTADIR Working Group on Oxygen Therapy. Association Nationale de Traitement a Domicile des Insuffisants Respiratoires.[see comment]. *Chest* 1996; 109(5):1144-1150. **No outcomes of interest**

86. Perrin C, El Far Y, Vandenbos F, Tamisier R, Dumon MC, Lemoigne F et al. Domiciliary nasal intermittent positive pressure ventilation in severe COPD: effects on lung function and quality of life. *European Respiratory Journal* 1997; 10(12):2835-2839. **Combined NIPPV & LTOT, no comparison group**
87. Pilling J, Cutaia M. Ambulatory oximetry monitoring in patients with severe COPD: a preliminary study. *Chest* 1999; 116(2):314-321. **Not LTOT**
88. Plywaczewski R, Sliwinski P, Nowinski A, Kaminski D, Zielinski J. Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy.[see comment]. *Chest* 2000; 117(3):679-683. **No outcomes of interest**
89. Revill SM, Singh SJ, Morgan MD. Randomized controlled trial of ambulatory oxygen and an ambulatory ventilator on endurance exercise in COPD. *Respiratory Medicine* 2000; 94(8):778-783. **Not LTOT**
90. Ringbaek TJ, Lange P, Viskum K. Are patients on long-term oxygen therapy followed up properly? Data from the Danish Oxygen Register. *Journal of Internal Medicine* 2001; 250(2):131-136. **No outcomes of interest**
91. Ringbaek TJ, Viskum K, Lange P. Non-continuous home oxygen therapy: utilization, symptomatic effect and prognosis, data from a national register on home oxygen therapy. *Respiratory Medicine* 2001; 95(12):980-985. **No PaO₂, part of Danish Registry (Ringbeck 2002)**
92. Roberts CM, Bell J, Wedzicha JA. Comparison of the efficacy of a demand oxygen delivery system with continuous low flow oxygen in subjects with stable COPD and severe oxygen desaturation on walking. *Thorax* 1996; 51(8):831-834. **Not LTOT, comparison of delivery systems**
93. Rooyackers JM, Dekhuijzen PN, Van Herwaarden CL, Folgering HT. Training with supplemental oxygen in patients with COPD and hypoxaemia at peak exercise. *European Respiratory Journal* 1997; 10(6):1278-1284. **Not LTOT**

94. Roselle S, D'Amico FJ. The effect of home respiratory therapy on hospital readmission rates of patients with chronic obstructive pulmonary disease. *Respiratory Care* 1982; 27(10):1194-1199. **Not LTOT**
95. Rudkin S. Home support for patients on long-term oxygen therapy. *Nursing Times* 1996; 92(34):34-35. **Not LTOT**
96. Sampablo I, Escarrabill J, Rosell A, Manresa F, Estopa R. Transtracheal catheter acceptance and adverse events in long-term home oxygen therapy. *Monaldi Archives for Chest Disease* 1998; 53(2):123-126. **AE of TT per se, not LTOT**
97. Sant'Anna CA, Stelmach R, Zanetti Feltrin MI, Filho WJ, Chiba T, Cukier A. Evaluation of health-related quality of life in low-income patients with COPD receiving long-term oxygen therapy. *Chest* 2003; 123(1):136-141. **No baseline data**
98. Schonhofer B, Barchfeld T, Wenzel M, Kohler D. Long term effects of non-invasive mechanical ventilation on pulmonary haemodynamics in patients with chronic respiratory failure. *Thorax* 2001; 56(7):524-528. **Not LTOT**
99. Shankar P, Muthiah MM. Audit on prescription of long-term oxygen treatment. *Clinical Performance & Quality Health Care* 2000; 8(3):134-135. **Report/audit**
100. Silverman BG, Gross TP, Babish JD. Home oxygen therapy in Medicare beneficiaries, 1991 and 1992. *Chest* 1997; 112(2):380-386. **No outcomes of interest**
101. Sivakumaran P, Garrett JE. The prescription of domiciliary long-term oxygen therapy in Auckland.[see comment]. *New Zealand Medical Journal* 1996; 109(1034):439-442. **No outcomes of interest**
102. Sliwinski P, Lagosz M, Gorecka D, Zielinski J. The adequacy of oxygenation in COPD patients undergoing long-term oxygen therapy assessed by pulse oximetry at home. *European Respiratory Journal* 1994; 7(2):274-278. **No outcomes of interest**
103. Soffer M, Tashkin DP, Shapiro BJ, Littner M, Harvey E, Farr S. Conservation of oxygen supply using a reservoir nasal cannula in

- hypoxemic patients at rest and during exercise. *Chest* 1985; 88(5):663-668. **No outcomes of interest**
104. Strom K, Boe J. A national register for long-term oxygen therapy in chronic hypoxia: preliminary results. *European Respiratory Journal* 1988; 1(10):952-958. **No outcomes of interest**
105. Strumpf DA, Millman RP, Carlisle CC, Grattan LM, Ryan SM, Erickson AD et al. Nocturnal positive-pressure ventilation via nasal mask in patients with severe chronic obstructive pulmonary disease. *American Review of Respiratory Disease* 1991; 144(6):1234-1239. **Comparison of NNV vs standard care, not all pts on supplemental oxygen**
106. Tiep BL, Nicotra B, Carter R, Belman MJ, Mittman C. Evaluation of a low-flow oxygen-conserving nasal cannula. *American Review of Respiratory Disease* 1984; 130(3):500-502. **Not LTOT, comparison of oxygen delivery system**
107. Tiep BL, Barnett J, Schiffman G, Sanchez O, Carter R. Maintaining oxygenation via demand oxygen delivery during rest and exercise. *Respiratory Care* 2002; 47(8):887-892. **Not LTOT**
108. Tzanakis N, Bouros D, Mamatzakis P, Samiou M, Siafakas NM. Long-term oxygen therapy on the island of Crete, Greece. *Monaldi Archives for Chest Disease* 1998; 53(5):533-536. **Not outcomes study**
109. Veale D, Chailleux E, Taytard A, Cardinaud JP. Characteristics and survival of patients prescribed long-term oxygen therapy outside prescription guidelines.[see comment]. *European Respiratory Journal* 1998; 12(4):780-784. **Duplicate paper, see Chailleux**
110. Vergeret J, Tunon DL, Douvier JJ, Freour P, Cardinaud JP, Courty G et al. Compliance of COPD patients with long term oxygen therapy. *European Journal of Respiratory Diseases - Supplement* 1986; 146:421-425. **No outcomes of interest**
111. Wedzicha JA. Domiciliary oxygen therapy services: clinical guidelines and advice for prescribers. Summary of a report of the Royal College of Physicians. *Journal of the Royal College of Physicians of London* 1999; 33(5):445-447. **Review**

112. Weitzenblum E, Apprill M, Oswald M. Benefit from long-term O₂ therapy in chronic obstructive pulmonary disease patients. *Respiration* 1992; 59:Suppl-7. **Review/report**
113. Wijkstra PJ, Guyatt GH, Ambrosino N, Celli BR, Guell R, Muir JF et al. International approaches to the prescription of long-term oxygen therapy.[see comment]. *European Respiratory Journal* 2001; 18(6):909-913. **Report**
114. Wright RW, Larsen DF, Monie RG, Aldred RA. Benefits of a community-hospital pulmonary rehabilitation program. *Respiratory Care* 1983; 28(11):1474-1479. **Not LTOT**
115. Wurtemberger G, Hutter BO. Health-related quality of life, psychological adjustment and compliance to treatment in patients on domiciliary liquid oxygen. *Monaldi Archives for Chest Disease* 2000; 55(3):216-224. **No baseline data**
116. Young IH, Crockett AJ, McDonald CF. Adult domiciliary oxygen therapy. Position statement of the Thoracic Society of Australia and New Zealand. *Medical Journal of Australia* 1998; 168(1):21-25. **Review**
117. Zack MB, Palange AV, Drews PG, Stehm D. Ventilatory and nonventilatory muscle exercise in COPD rehabilitation. *Respiratory Therapy* 1984; 14(5):41-45N **LTOT**
118. Zeng GB, Zhang ZX, Xu YJ, Duan SF. Effects of exercise on pulmonary gas exchange and oxygen transport in chronic obstructive pulmonary diseases. *Chinese Medical Journal* 1992; 105(1):49-54. **Not LTOT**
119. Zielinski J. Indications for long-term oxygen therapy: a reappraisal. *Monaldi Archives for Chest Disease* 1999; 54(2):178-182. **Review**
120. Zinman C, Richards GA, Taylor R, Mer M. Long-term domiciliary oxygen therapy--the Johannesburg Hospital experience. *South African Medical Journal* 2000; 90(6):617-621. **No outcome of interest**